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ABSTRACT 
  
 
Ping Li 
 
Grapefruit juice (GFJ) is we ll known to be a potent inhibitor of the CYP3A 
enzyme leading to drug-drug interactions .  This study describes a newly identified 
potential of GFJ in mediating pharmacokinetic drug-drug interactions due to its 
capability of esterase inhibition.  The study demonstrates that GFJ inhibits 
purified porcine esterase activity towards para-nitrophenylacetate (PNPA) and 
the prodrugs lovastatin and enalapril.  In rat and human hepatic or gut S9 
fractions and rat gut lumen GFJ inhibited the hydrolysis of enalapril and lovastatin, 
which are known to be metabolized principally by esterases, with lovastatin 
metabolized also by CYP3A.  In Caco-2 cells, permeability of these prodrugs was 
increased in the presence of GFJ.  In rats, oral coadministration of GFJ or an 
esterase inhibitor bis-(p-nitrophenylphosphate) with the prodrugs led to 
respective increases in plasma AUC for enalaprilat for lovastatin acid.  Studies in 
portal vein cannulated rats demonstrated that in addition to CYP3A inactivation, 
GFJ also played a significant role in the decreased esterase activity leading to 
enhancement of exposure to the active drugs in rats.   
 
To identify the GFJ components responsible for this new GFJ-prodrug interaction, 
the esterase inhibitory potential of ten constituitive flavonoids and 
furanocoumarins was investigated.  The furanocoumarins bergamottin, 6’,7’-
dihydroxybergamottin and bergapten and the glycosidic flavonoids naringin and 
hesperidin, at concentrations found in GFJ or higher did not inhibit the hydrolysis 
of PNPA by purified porcine esterase and human liver microsomes.  However, 
the flavonoid aglycones morin, galangin, kaempferol, quercetin, and naringenin 
showed appreciable inhibition of PNPA hydrolysis.  In Caco-2 cells, the 
permeability coefficient of prodrug lovastatin and enalapril was increased in the 
presence of the active flavonoids kaempferol and naringenin, consistent with 
inhibition of esterase activity. In rats, oral coadministration of kaempferol and 
naringenin with these prodrugs led to significant increases in plasma exposure to 
the active acids.  Overall, a series of flavonoids present in GFJ are identified as 
carboxylesterase inhibitors, of which kaempferol, and naringenin are shown to 
mediate pharmacokinetic drug interaction with prodrugs lovastatin and enalapril 
due to their ability to inhibit esterase.     
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INTRODUCTION 
 
 
Since the first report of the grapefruit juice (GFJ) effect on the oral bioavailability 
of felodipine (Bailey et al., 1989, 1991), GFJ has been shown to increase oral 
exposure of many compounds (Kupferschmidt et al., 1995, Benton et al., 1996, 
Ducharme et al., 1995).  These drugs differ in their chemical and 
pharmacological properties, but are, in common, extensively metabolized by 
CYP3A. The mechanism of action was postulated to be competitive and 
mechanism-based inhibition of CYP3A4/5 (hereafter referred to  as CYP3A) in the 
small intestine by GFJ (Schmiedlin-Ren et al. 1997; He et al., 1998).  The effect 
is believed to be at the level of intestine because GFJ showed little effect after 
single intravenous administration (Kupferschmidt et al., 1995; Ducharme et al., 
1995).  Although some recent reports point to the inhibitory effects of grapefruit 
juice on the function of P-glycoprotein (Zhou et al., 2004) and Organic Anion 
Transporting polypeptides (OATP) (Dresser et al., 2002), the contribution to the 
bioavailability of drugs that are substrates of P-glycoprotein and OATP has not 
been well established.  Since 1998, the effect of grapefruit juice ingestion on the 
pharmacokinetics of orally administered drugs have been reported for 40 drugs 
(Saito  et al., 2005), generally related to CYP3A inhibition.  Effect of repeated 
intake of GFJ on CYP3A activity (Culm-merdek et al, 2006) has been reported.  It 
is interesting to note that the magnitude of GFJ effect varied greatly, and we 
noted that the magnitude of GFJ effect was not proportional to the extent of 
CYP3A-mediated intestinal metabolism.  As an example, cyclosporine, which is 
extensively metabolized in human intestine by CYP3A, interacted weakly with 
GFJ (Ducharme et al., 1995), the interaction unlikely to be of clinical significance.  
However, lovastatin which is also metabolized in human intestine by CYP3A and 
esterase, led to one of the most potent and clinically significant drug-GFJ 
interactions.  The oral bioavailability of lovastatin in humans was increased >15-
fold by GFJ (Kantola et al., 1998).  Because lovastatin is a CYP3A substrate, this 
interaction was postulated to be the result of CYP3A inhibition.  However, since 
lovastatin (a lactone) is also known to be hydrolyzed by esterase to a 
 v 
hydroxyacid analog (active drug), and the carboxylesterase (CE) mediated 
hydrolysis of lovastatin is also a major metabolic pathway (Ha lpin et al., 1993), 
we hypothesized that the interaction between GFJ and lovastatin is cumulative of 
CYP3A and esterase inhibition.  There are a few reports on the interactions 
between esterase inhibitors and ester compounds, including naturally occurring 
products.    Extract of strawberry and banana juice inhibited the intestinal 
esterase-mediated hydrolysis of antiviral ester prodrug bis (POC)–PMPA 
(VanGelder et al., 1999) and increased absorption of the ester prodrug tenofovir 
disoproxil in rat ileum by inhibiting its intestinal metabolism (VanGelder et al., 
2000).  Intestinal absorption of tenofovir disoproxil fumarate was enhanced also 
by a defined esters mixture (Van Gelder et al., 2002). However, there are no 
reports on GFJ mediated interactions due to esterase inhibition. We designed 
and performed these studies, described in three separate sections , to test our 
hypothesis that GFJ inhibits esterases. In Part I, carboxyl esters lovastatin and 
enalapril were selected as model compounds to investigate the GFJ-carboxyl 
ester interactions. In vitro, evaluation of the esterase-mediated changes in the 
permeability and metabolism in in vitro systems, and in vivo rat exposure to 
enalapril and lovastatin when coadministered with GFJ are described.  In Part II, 
esterase inhibition potential of ten grapefruit juice components towards PNPA 
hydrolysis as well as the effect of two selected carboxyl esters on the esterase 
mediated changes in the permeability in in vitro systems, and in in vivo rat 
exposure to active acids of enalapril and lovastatin upon coadministration are 
described.  In Part III, the interaction mechanism of grapefruit components with 
enalapril and CPT11, two selective substrates for human carboxylesrease I and II, 
respectively, were further studied.  Every experiment in this dissertation was 
performed in Millennium Pharmaceuticals Inc. (Cambridge, MA), and all animal 
in-life studies were performed by Comparative Medicine Group. 
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PART I 
 
ESTERASE INHIBITION BY GRAPEFRUIT JUICE LEADS TO A NEWLY 
IDENTIFIED DRUG INTERACTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1. INTRODUCTION 
 
 In humans, carboxylesterases (CEs) metabolize a wide variety of esterified 
drugs such as meperidine (Zhang et.al, 1997) and cefuroximine axetil (Campbell 
et al., 1987), anticancer agents CPT11 (Potter et al., 1998; Danks et al., 1999) 
and capecitabine (Campbell et al., 1987), as well as the illicit street drugs heroin 
and cocaine (Pindel et al., 1997).  In general, CEs are expressed in tissues likely 
to be exposed to such agents including the liver, small intestine, kidney, etc 
(Satoh T. and Hosokawa M., 1998).  Therefore, agents affecting CEs could result 
in alterations in distribution and clearance of esterified drugs leading to potential 
CE-mediated drug interactions.  There are a few reports on the interactions 
between esterase inhibitors and ester compounds, including naturally occurring 
products.  Extract of strawberry and banana juice inhibited the intestinal 
esterase-mediated hydrolysis of antiviral ester prodrug bis (POC)–PMPA 
(VanGelder et al., 1999) and increased absorption of the ester prodrug tenofovir 
disoproxil in rat ileum by inhibiting its intestinal metabolism (VanGelder et al., 
2000).  Intestinal absorption of tenofovir disoproxil fumarate was enhanced also 
by a defined esters mixture (Van Gelder et al., 2002). However, there are no 
reports on GFJ mediated interactions due to esterase inhibition.  In this study we 
used carboxyl esters lovastatin and enalapril as model compounds to investigate 
the GFJ-carboxyl ester interactions.  Lovastatin, a prodrug for the treatment of 
hypercholesterolemia, is metabolized by CYP3A4 to oxidative products and 
hydrolyzed by carboxylesterase to its active form lovastatin hydroxyl acid 
(hereafter referred to as lovastatin acid) (Halpin et al., 1993).   The hydrolysis 
occurs in gut, liver and plasma and is considered as its major metabolic pathway 
(Vree et al., 2003).  Lovastatin absorption is about 30% in humans as well in rats 
(Duggan et al., 1988).  The similarity of lovastatin absorption in rats and humans 
led us to employ the rat as a preclinical animal model to elucidate ester mediated 
alterations in systemic exposure in rats upon coadministration with GFJ. 
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The second compound selected for the current studies was enalapril, a prodrug 
for the treatment of hypertension.  Enalaprilat, the hydroxyacid form of this alkyl 
ester prodrug, is a potent inhibitor of diacidic angiotensin converting enzyme 
(ACE).  The bioavailability of enalaprilat in humans (Hockings et al., 1986) is 
increased to 50-60% when given as enalapril, compared to only 3% when 
enalaprilat is administrated orally.  Enalapril is metabolized only by 
carboxylesterase (Tocco et al., 1982; Drummer et al., 1990), and the in vitro 
and in vivo results indicate that enalapril is primarily absorbed by a non-
saturable, passive diffusion process and is not a suitable model compound for 
studying transporter-related interaction in rats (Morrison et al., 1986).  Thus, 
Enalapril is also considered to be an ideal candidate for testing inhibition of 
esterase activity with GFJ in the rat model.  Evaluation of the esterase-
mediated changes in the permeability and metabolism in in vitro systems, and 
in vivo rat exposure to enalapril and lovastatin when coadministered with GFJ 
are described in this report. 
 
2. OBJECTIVES 
 
The objectives of this study were a) to evaluate the effect of GFJ on esterase 
activity b) to evaluate effect of GFJ on hydrolysis of ester prodrugs enalapril and 
lovastatin by human intestinal and liver S9, c) to evaluate the effect of GFJ on 
permeability of enalapril and lovastatin across Caco-2 membrane, d) to evaluate 
the effect of GFJ on the hydrolysis of enalapril and lovastatin in vitro in rats, e) to 
evaluate the effect of GFJ on the hydrolysis of enalapril and lovastatin in vivo in 
rats, and f) to differentiate between CYP3A, esterase, and Pgp effect of GFJ. 
 
3. MATRIALS AND METHODS  
 
3.1 Materials 
 GFJ (Minute Maid frozen concentrates) cans were purchased locally (Cambridge, 
MA); enalapril, para-nitrophenylacetate, p-nitrophenol, phenylmethylsulfonyl 
 4 
fluoride (PMSF), bis-p-nitrophenylphosphate (BNPP), glycylsarcosine (Gly-Sar), 
and 10X Hank’s balance buffer were purchased from Sigma (St. Louis, MO); 
Enalaprilat was purchased from Toroto Research Chemicals Inc. (North York, 
ON). GF120918 was kindly provided by Dr. Shimoga Prakash. The GFJ used in 
the study was prepared by 1:3 dilutions with water, unless stated otherwise.  Rat 
liver and intestinal microsomes and S9, and human liver S9 (pool of 50 donors) 
were purchased from Xenotech (Lenexa, KS); human intestinal S9 (pool of 4 
donors) was purchased from Tissue Transformation Technologies (Baltimore, 
MD); purified porcine esterase was purchased from Sigma (St. Louis, MO); Caco-
2 cells were obtained from American Type Culture Collection (Manassas, VA); 
and human PEPT1-expressed transportocytes were purchased from BD Gentest 
(Woburn, MA).  
 
3.2 The effect of GFJ on purified porcine esterases  
 
Hydrolysis of para-nitrophenylacetate (PNPA) 
 
Purified porcine esterase of 1, 2.5, and 5 munit/mI was incubated at room 
temperature with 39, 78, 156, 312, 625, 1250, and 2500 µM PNPA in phosphate 
buffer (pH, 7.4) in a final volume of 100 µL.  The formation of product, para-
nitrophenol, was monitored spectrophotometrically at 405 nm at 0, 2, and 4 min.  
 
Effect of GFJ on hydrolysis of para-nitrophenylacetate 
 
Purified porcine esterase (5 munit/mL) was incubated at room temperature with 
PNPA (0.67 mM) in phosphate buffer (0.1 M; pH, 7.4) in the presence or absence 
of 1:3 diluted GFJ (pH 7.4; 0, 20 and 40% final concentration in the incubation 
mixture) in a final volume of 100 µL.  The formation of product, para-nitrophenol, 
was monitored spectrophotometrically at 405 nm at 2 min. 
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Effect of GFJ on hydrolysis of enalapril and lovastatin by purified porcine 
esterases  
 
Purified porcine esterase (0.1 unit/mL) was incubated at 37°C with enalapril and 
lovastatin (5 µM) in 0.1 M potassium phosphate buffer, pH 7.4, in the presence or 
absence of GFJ (pH 7.4; 0, 20% and 40%) in an incubation volume of 0.1 mL.  
Enalapril incubations were quenched after 10 min and lovastatin incubations after 
30 min by the addition of 10 µL of glacial acetic acid.  The quenched mixtures 
were spiked with varied amounts of GFJ to keep the amount of GFJ equal in 
each sample.   The incubation mixtures then were extracted with 100 µL of 1% 
acetic acid in acetonitrile containing carbutamide as an internal standard.  The 
concentration of enalaprilat and lovastatin acid in the supernatants were 
determined by LC/MS/MS. 
 
3.3 Effect of GFJ on Hydrolysis of Enalapril and Lovastatin in Human and Rat  
In Vitro System 
 
Effect of GFJ on hydrolysis of enalapril and lovastatin in human and rat intestinal 
and liver S9 fractions.   
 
Human and rat intestinal or liver S9 (2.0 mg/ml) were incubated at 37°C with 
enalapril (5 µM) in 0.1 M potassium phosphate buffer (pH 7.4) in the presence or 
absence of GFJ (pH 7.4; 0, 20% and 40%); or lovastatin (5 µM) in Hank’s 
balanced buffer (pH 6.0) in the presence or absence of GFJ (pH 6.0; 0, 20% and 
40%). A pH of 6.0 was used to reduce chemical hydrolysis of lovastatin.  Liver S9 
incubations were carried out for 10 min and intestinal S9 incubation for 30 min.  
Reactions were terminated by the addition of 10 µL of glacial acetic acid.  The 
incubation mixtures were processed as described in the previous section. 
 
Effect of GFJ on hydrolysis of enalapril and lovastatin in rat intestinal lumen 
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 Rat lumen was collected by rinsing the small intestine (30 cm length from the 
end of the stomach) of overnight fasted SD rats obtained from Hilltop Laboratory 
Animals, Inc. (Scottdale, PA) (n=3) with 1 x 2 mL phosphate buffer (pH, 7.4).  
The pH of the pooled lumen was adjusted to 7.0 in a final volume of 7.0 mL.  
Lumen was used fresh on the day of collection. 
 
A 50 µL aliquot of rat lumen was incubated with lovastatin and enalapril (5 µM) at 
37°C in the presence of 50 µL of phosphate buffer (pH, 7.0 or 3.5) or 50 µL of 
GFJ (40% and 80%) at pH, 7.0 or 3.5.  After 30 min incubations, the reactions 
were terminated by adding an equal volume of acetonitrile containing 
carbutamide as the internal standard.  The samples were centrifuged at 3,000x g 
for 10 min.  Supernatants were dried under nitrogen and the residues were 
reconstituted into 0.1% formic acid in 10% acetonitrile and analyzed with 
LC/MS/MS for concentration of lovastatin acid and enalaprilat. 
 
Metabolism of lovastatin in human liver microsomes  
 
Lovastatin (50 µM) was incubated with human liver microsomes (2 mg/ml) in the 
presence or absence of NADPH (2.0 mM) for 30 min in an incubation volume of 
0.3 mL; reactions were terminated with the addition of an equal volume of 
acetonitrile.  The supernatants were subjected to LC/MS/MS analysis for 
identifying lovastatin metabolites. 
 
3.4 Effect of GFJ on A-to-B Permeability of lovastatin and enalapril across Caco-
2 membrane 
 
Caco-2 cells   
 
Caco-2 cells obtained from American Type Culture Collection (Manassas, VA)  
were cultured in 150-cm2 tissue culture T-flasks for subsequent plating onto 24-
Transwell plate (0.33 cm2/well, 0.4 µM pore size; Costar, Cambridge, MA).  
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Briefly 1 x 105 cells were suspended in 0.2 mL of culture medium (Dulbecco’s 
modified Eagle’s medium with 0.1 mM nonessential amino acids, 2 mM L-
glutamine, 4.5 g/L glucose, and 10% fetal bovine serum) and added to the upper 
chamber (Apical) of each filter membrane of a Transwell plate.  One milliliter of 
cell-free culture medium was added to the lower chamber (Basolateral).  The 
Transwell plates were then incubated at 37°C in an atmosphere of 5% CO2 in air 
and 90% humidity.  The culture media was changed every other day.  Confluent 
cell monolayers were obtained within 5 to 7 days after plating.  The 
transepithelial electrical resistance (TEER), as measured by an epithelial 
volthommeter (World Precision Instruments, Inc., Sarasota, FL), gradually 
increased and reached a plateau afte r day 5, indicating the formation of tight 
junctions.  Monolayers with TEER values greater than 250 ohm/cm2 were used.   
CYP3A and esterase activities of Caco-2 homogenates 
Caco-2 cells were harvested by trypsinization. Harvested Caco-2 cells were 
washed one time with transport buffer and homogenized in transporter buffer.  
The protein concentration of Caco-2 homogenates was determined using BCA 
protein assay (Pierce, Rockford, IL).  Midazolam or lovastatin (5 µM) each was 
incubated with Caco-2 homogenates (2 mg/mL) at 37°C.  After 0, 10, 20, and 40 
min incubation, reactions were terminated by adding an equal volume of 
acetonitrile containing carbutamide as the internal standard.  The concentrations 
of 1-hydroxy and 4’-hydroxy midazolam (MD) in the supernatants from 
midazolam incubations; lovastatin and lovastatin acid in the supernatants from 
lovastatin incubations were determined by LC/MS. Hydroxylovastatin metabolites 
from lovastatin incubations were identified with LC/MS/MS. 
Enalapril and lovastatin A-to-B permeability in Caco-2 cells  
Caco-2 cell cultures were prepared as described above .  Single directional 
transport studies were performed at 37°C in air.  Prior to each experiment, the 
confluent cell monolayer on TranswellTM inserts were washed and equilibrated for 
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30 min with transport medium [Hanks' balanced salt solution containing 10 mM 
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) and 10 mM 
glucose, pH 7.4]. The experiment was  initiated by adding a solution of lovastatin 
in the transport medium at pH 7.0 or enalapril in the transport medium at pH 6.0, 
containing various proportions of 1:3 diluted GFJ (0, 6.2, 12.5, 25, and 50% final 
concentration in the incubation) to the apical compartment. To evaluate effect of 
Pgp on lovastatin permeability, GF120918 (2 µM final concentrations in the 
incubation)  shown in Figure 54 was added into lovastatin stock solution to the 
donor side and the buffer of the receiver side.  At 15, 30, 45, and  60 min, aliquots 
were withdrawn from the basolateral side and replaced immediately with an equal 
amount of fresh transport media, except at the  60-min time point (the end of the 
incubation). 
After the permeability studies described in the previous section, TEER values 
were measured again to assure the integrity of the cells.  The cells were washed 
three times with cold transport medium and then were lysed with 1% acetic acid 
in water.  The cell lysates were extracted with acetonitrile containing carbutamide 
as interna l standard and centrifuged at 3000xg for 10 min.  The supernatants 
were collected and analyzed using LC/MS/MS  
 
Enalapril uptake in Caco-2 cells 
 
 Prior to the experiment, the confluent cell monolayers on TranswellTM inserts 
were washed and equilibrated for 15 min with transport medium, pH 6.0.  
Enalapril in transport medium, containing various amount of GFJ (0, 6.2, 12.5, 
and 25%), was added to the apical compartment.  The uptake study was carried 
out for 5 min at room temperature and was stopped by aspirating out the solution.  
The cells were washed three times with cold transport medium and then were 
lysed with water.  The cell lysates were extracted with acetonitrile containing 
carbutamide as internal standard and centrifuged at 3000xg for 10 min.  The 
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supernatants were collected and analyzed using LC/MS/MS for concentrations of 
the prodrug and the active acid.  
 
Enalapril uptake in human PEPT1-expressed transportocytes  
 
Enalapril uptake in human PEPT1-expressed transportocytes was performed 
according to a modified procedure suggested by the manufacture (BD Gentest).  
Simply, transportocytes (oocytes) were placed in individual wells of 24 well plate 
(8-10 oocytes in each well) and washed with sodium buffer pH 6.5 three times.  
Enalpril or Gly-Sar (20 µM), a substrate for PEPT1 shown in Figure 54, 
respectively, in uptake buffer (Na+ buffer, pH 6.5) was added into each well to 
start the uptake under room temperature. After one hour incubation, oocytes 
were washed with cold sodium uptake buffer three times, and then lysed with 
acetonitrile containing carbutamide as the internal standard. The cell lysates 
were centrifuged at 3000xg for 10 min, and the supernatants were collected and 
analyzed using LC/MS for the content of Gly-Sar and enalapril, respectively.  
Water-injected oocytes were used as a negative control; Gly-Sar was used as a 
positive control. 
 
Binding of Lovastatin to GFJ Pulp  
 
Lovastatin (20 µM) was spiked into transport buffer containing GFJ at various 
concentrations (0, 6.25, 12.5, 25.0, 50.0, and 100%); these samples were 
centrifuged at 10,000x g for 5 min.  The content of lovastatin in the supernatants 
was analyzed by LC/MS/MS . 
 
3.5 Pharmacokinetic studies in SD rats  
 
Pharmacokinetics experiments with enalapril and lovastatin were performed in 
male Sprague-Dawley rats (n=3 or 4, each group) weighing 280 to 350 g 
implanted with either jugular vein cannula or both jugular and portal vein 
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cannulas.  Animals were fasted overnight and for the duration of the study.  
Water was provided ad libitum.  
For oral application, jugular vein cannulated rats were dosed by gavage (10 
mL/kg) with enalapril or lovastatin (10 mg/kg) in (a) water (pH 3.5)*, (b) GFJ of 
three strengths (1:3 diluted, 1:2 diluted, Concentrate), (c) water, and (d) bis-p-
nitrophenylphosphate (BNPP) shown in Figure 54 (25 mg/kg, PO).   Venous 
blood samples (0.3 mL) were collected from jugular vein catheters (JVC) into 
heparin tubes containing 3 µL of 200 mM PMSF and 5 µL of acetic acid (60% in 
water) predose and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h postdose.  Samples were 
centrifuged for 5 min at 15000 rpm, plasma were collected and frozen at -800C 
until analyzed. * Water (pH 3.5 ) was prepared by spiking glacial acetic acid into 
water to adjust pH of water to 3.5. 
For GFJ pretreatment studies, portal vein cannulated (PVC) rats pretreated at -
15 and -2 hr with water (pH 3.5) (Group A), and with GFJ (1:3 diluted, 10 mL/kg; 
Groups B and C) were dosed orally with lovastatin (10 mg/kg ) as a solution in 
water (pH 3.5) and in GFJ (1:3 diluted).   Portal blood samples were collected 
from PVC rats predose and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h postdose.  
Samples were centrifuged for 5 min at 15,000 rpm, plasma were collected and 
frozen at -80ºC until analyzed. 
For intravenous studies, JVC rats were pretreated orally with water (pH 3.5), or 
GFJ (1:3 diluted; 10 mL/kg) at -0.5 hr prior to a slow IV bolus dose of enalapril at 
2 mg/kg as a saline solution (5 mL/kg) or lovastatin at 2 mg/kg in a 10:40:10:40 
mixture of ethanol, polyethylene glycol 400, N,N-dimethylacetamide and saline  (5 
mL/kg).   Venous blood samples were collected predose and at 0.083, 0.25, 0.5, 
1, 2, 4, 6, 8 and 24 h postdose. 
 
LC/MS/MS analysis  
 
The plasma samples were treated with 3 volumes of acetonitrile containing 
carbutamide (0.2 µM) to precipitate protein.  Control plasma, with esterase 
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inactivated by the addition of 1% acetic acid and 2 mM phenylmethylsulfonyl 
fluoride (PMSF) shown in Figure 54, was used to construct plasma standard 
curves.  Half of the volume of supernatant was dried down under nitrogen, and 
reconstituted with 150 µL of 5% acetonitrile in 0.1% formic acid, and was 
analyzed by an LC/MS/MS.  The LC/MS/MS system consisted of a binary high 
performance liquid chromatography pump (1100; Agilent Technologies, Palo Alto, 
CA), an HTS PAL autosampler (LEAP Technologies, Carrboro, NC), and a triple-
quadrupole mass spectrometer (API-4000; Applied Biosystems, Foster City, CA).  
Separation was performed on an YMC-ODS-AQ C18 column (30 mm ´ 2.0 mm; 
Waters, Milford, MA) using mixtures of formic acid (0.1%) in water and 
acetonitrile as a mobile phase.  The mass spectrometer was operated in the 
multiple reaction monitoring mode (MRM) using positive ion electrospray 
ionization. MRM was set at m/z 405.3 ?  285.3 for lovastatin, m/z 423.3 ?  303.4 
for lovastatin acid, m/z 439.4 ?  283.4 for 6’ß-hydroxylovastatin acid, m/z 421.4 
?  283.4 for 6’ß-hydroxylovastatin, m/z 377.1 ?  233.9 for enalapril, m/z 349.3 ?  
206.4 for enalaprilat, and m/z 272.4 ?  156.2 for carbutamide (internal standard).  
The concentration range of standard curves for enalapril, enalaprilat, lovastatin 
and lovastatin acid, respectively was generally between 1 to 2500 nM with 12 
points, and the quantification limit for enalapril, enalaprilat, lovastatin and 
lovastatin acid was generally 2 nM. 
 
Data analysis   
 
The pharmacokinetic parameters were calculated by noncompartmental analysis 
using WinNonlin Software Version 5.0 (Pharsight, Mountain view, CA).  The 
statistical significance test was performed by using Student T-Test.     
 
4. RESULTS AND DISCUSSION 
 
4.1 Results 
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PNPA hydrolysis by purified porcine esterases 
PNPA hydrolysis by purified porcine esterase is summarized in Figure 1.  At the 
protein concentration of 5 munit/mL, linear kinetics was observed at PNPA 
concentration up to 1.25 mM at 2 min incubation, thus a concentration of PNPA 
0.68 mM was selected for the following inhibition studies. 
 
Effect of GFJ on purified porcine esterases  
 
 Effect of GFJ on the hydrolysis of PNPA, enalapril, and lovastatin by purified 
porcine esterases, as measured by the formation of the hydrolysis product, is 
shown in Figure 2.  The respective hydrolytic activity with 20 and 40% GFJ were 
decreases to 65% and 54% for PNPA; 50% and 31% for enalapril; and 44% and 
26% for lovastatin relative to the control values. 
  
Inhibitory effect of GFJ on hydrolysis by human intestinal and liver S9   
 
The percent of lovastatin hydrolyzed was reduced to 54%, 46% and 38% of the 
control in human liver S9; 55%, 52% and 47% of the control in human intestinal 
S9 using 10%, 20% and 40% GFJ, respectively (Figure 3A).  The percent of 
enalapril hydrolyzed was reduced to 87%, 90% and 78% of the control in human 
liver S9 using 10%, 20%, and 40% GFJ, respectively (Figure 3B).  Intestinal S9 
showed weak hydrolytic activity towards enalapril. 
 
Inhibitory effect of GFJ on hydrolysis of lovastatin and enalapril along GI tract in 
rats  
 
The percent of lovastatin hydrolyzed was reduced to 78%, 65% and 63% of the 
control in rat liver S9; and 55%, 59% and 43% in rat intestinal S9 by 10%, 20% 
and 40% GFJ (Figure 4A), respectively.  In rat lumen, lovastatin hydrolysis was 
reduced to 65% and 48% of the control by 20% and 40% GFJ at pH 7.0 (Figure 
4B); and 34% and 26% of the control by 20% and 40% GFJ at pH 3.5 (pH of 
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GFJ).  Enalapril hydrolysis was reduced to 80%, 68% and 49% of the control in 
rat liver S9; and 83%, 70% and 61% in rat intestinal S9  by 10%, 20% and 40% 
GFJ (Figure 5A), respectively.  In rat lumen, the hydrolysis was reduced to 52% 
and 45% by 20% and 40% GFJ at pH 7.0 (Figure 5B); and 59% and 24% by 20% 
and 40% GFJ at pH 3.5. 
 
CYP3A and esterase activity of Caco-2 homogenates  
 
The CYP3A activity of Caco-2 homogenates was characterized by the formation 
rate of 1’-hydroxy- and 4-hydroxymidazolam using midazolam as the substrate.  
As depicted in the Figure 6, the amount of two hydroxyl metabolites formed 
during the forty minute incubation was negligible that suggests CYP3A activity in 
this Caco-2 cells is negligible.   No hydroxylated metabolites of lovastatin were 
detected in the lovastatin incubation.  Hydrolysis of lovastatin in Caco-2 
homogenates (Figure 7) showed that 10% of lovastatin was hydrolyzed to 
lovastatin acid in the forty minute incubation.    
 
Binding of lovastatin to GFJ pulp 
 
With the increase in the concentration of GFJ, the percentage remaining of 
lovastatin in the pulp free supernatant was decreased.    As summarized in Table 
1, the percentage remaining of lovastatin was 92.6, 87.8, 74.1, 68.2, 64.2% in the 
presence of GFJ at 6.25, 12.5, 25, 50, and 100%, respectively. 
 
Effect of GFJ on A-to-B permeability in Caco-2 cells  
 
The permeability of lovastatin was increased by 40% and 22% with 6.25% and 
12.5% GFJ (1:3 diluted), but permeability was decreased by 4% and 50% with 
25% and 50% GFJ, respectively (Figure 8A).  In Caco-2 cells at 1 hr, the 
intracellularly trapped lovastatin was decreased to 95%, 63%, 72% and 58%; and 
lovastatin acid was significantly decreased to 71%, 40%, 29% and 20% with 6.25, 
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12.5, 25 and 50% GFJ, respectively.   Overall, the corresponding ratio of 
lovastatin acid to lovastatin (Figure 8B) was decreased to 81%, 64%, 42%, and 
34% by GFJ.  The permeability of enalapril was significantly increased by 30%, 
52%, 133% and 88% with 6.25%, 12.5%, 25% and 50% GFJ, respectively 
(Figure 9A).  The corresponding intracellularly trapped enalapril in Caco-2 at 1 hr 
was increased to 139%, 156%, 162% and 187% of the control; and enalaprilat 
was decreased to 88%, 77%, 70% and 68%.  Overall, the corresponding ratio of 
enalaprilat to enalapril (Figure 9B) was decreased to 64%, 49%, 43%, and 35% 
of the control. 
 
Uptake rate of enalapril in Caco-2 cells    
 
Shown in Figure 10A, the uptake rate of enalapril in Caco-2 was 1.71 
pmol/min/cm2, whereas the values were 1.99, 1.91 and 2.02 pmol/min/cm2 in the 
presence of 6.25, 12.5 and 25% GFJ (1:3 diluted), respectively.  The uptake rate 
of enalapril in Caco-2 in the presence of Gly-Sar (a known PEPT1 substrate; 10 
mM) did not change significantly, with the value being 1.99 pmol/min/cm2.   
 
Uptake rate of enalapril in human PEPT1-expressed transportocytes 
 
Figure 10B shows uptake rate of enalapril and Gly-Sar, a known human PEPT1 
substrate in human PEPT1-expressed and water–injected transportocytes.  No 
distinguishable  difference of the uptake rate of enalapril between PEPT1-
expressed and water injected transportocytes was observed.  The uptake rate of 
enalapril is 0.42 and 0.50 in human PEPT1-expressed and water injected 
transportocytes, respectively.  The uptake rate of Gly-Sar is 27.5 and 0.66 in 
human PEPT1-expressed and water injected transportocytes, respectively. 
 
Identification of lovastatin metabolites in human liver microsomes incubations 
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Lovastatin (Figure 51) has two carboxylate groups, a lactone and 2-
methylbutanoic acid ester.  The metabolite from lactone hydrolysis (m/z 405.4 + 
18) was detected in the human microsomal incubation (Figures 11, 14, and 19), 
but the metabolite resulting from hydrolysis of 2-methylbutanoic acid ester was 
not detected (Figure 15). Consistent with the published data (Halpin et al. 1993), 
hydrolysis of lovastatin occurs on the lactone ring.  Besides, two hydroxyl 
metabolite (m/z 405.4 +16) and two  hydroxyacids of the hydroxyl metabolite (m/z 
405.4 +34), hydroxylacid, were detected in the human liver microsome 
incubations (Figures 12, 16, and17). The four metabolites have distinguishable 
retention time with 5.02 and 6.19 min for the two hydroxyl metabolites, 4.36 and 
5.67 min for the two hydroxyacid metabolites, respectively.  MS/MS data, 
depicted in Figures 18, 20, 21, 22, and 23, suggested that the peak with m/z 
421.3 and retention time (5.02 min) is 6’ß-hydroxylovastatin, and the peak with 
m/z 439.4 and retention time 4.74 min is its hydroxyacid (6’ß-hydroxylovastatin 
acid).  PK plasma samples were analyzed with LC/MS using multiple reaction 
monitoring mode (MRM).  MRM was set at m/z 439.4 ?  283.4 for 6’ß-
hydroxylovastatin acid and 421.4 ?  283.4 for 6’ß-hydroxylovastatin.   The 
retention time of metabolite 1(439.4 ?  283.4) and metabolite 2 ( 421.4 ?  283.4) 
found in PK plasma samples was 4.36 and 5.02 min, respectively, consistent with 
the observations in human liver microsomes incubation.   
 
Effect of BNPP on the PK of enalaprilat and lovastatin acid in rats  
 
The plasma concentration-time profiles of enalaprilat and lovastatin acid following 
oral co-administration of enalapril and lovastatin (10 mg/kg), respectively, with 
water or with BNPP (25 mg/kg) are shown in Figures 24A and 24B, and the PK 
parameters are listed in Table 2.  Generally, the exposure of rats to both 
enalaprilat and lovastatin acid was increased by BNPP with the mean Cmax  and 
AUC  increased by 56% and 57% for enalaprilat, and 235% and 141% for 
lovastatin acid, respectively.     
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Effect of GFJ on oral PK of lovastatin acid and enalaprilat in rats 
 
 The plasma concentration-time profiles of enalaprilat or lovastatin acid following 
oral co-administration of enalapril or lovastatin (10 mg/kg) with water (pH 3.5) 
(pH 3.5) or GFJ (1:3 diluted, 1:2 diluted, and the concentrate) are shown in 
Figures 25A and 25B.  The Cmax and AUC of lovastatin acid were significantly 
increased in rats following oral administration of lovastatin with GFJ (Table 3).  
The AUC was increased by 279%, 157% and 170%; and Cmax was increased by 
311%, 135% and 157% upon coadministration with 1:3 diluted, 1:2 diluted, and 
concentrated GFJ, respectively.  Similarly the Cmax and AUC of enalaprilat were 
increased in rats following oral coadministration of enalapril with GFJ (1:3 diluted, 
1:2 diluted, and the concentrate), with the respective AUC increased by 65% , 
70% and 16% (Table 3); and Cmax increased by 60% and 50% (1:3 diluted and 
1:2 diluted GFJ), and decreased by 43% by GFJ concentrate, relative to the 
control.  
 
Effect of GFJ pretreatment on oral PK of lovastatin in portal vein cannulated rats  
 
The portal vein plasma concentration-time profiles of lovastatin acid (Figure 26A), 
lovastatin acid plus lovastatin (Figure 26B), 6’ß-hydroxylovastatin (Figure 27A), 
and its hydroxy acid (6’ß-hydroxylovastatin acid) (Figure 27B) following oral 
administration of lovastatin (10 mg/kg) to rats pretreated (-2 hr and -15 hr) either 
with water (pH 3.5) or 1:3 diluted GFJ showed graded effect of GFJ pretreatment. 
The 6’ß-hydroxylovastatin and the corresponding hydroxyacid were identified by 
LC/MS/MS spectral comparison with the published data (Halpin et al., 1993), and 
quantitated in plasma using lovastatin standard curves.  The portal plasma AUC 
of lovastatin acid on pretreatment with water (pH 3.5) (Group A) versus GFJ 
(Group B) showed 49% increase in AUC in the GFJ pretreated rats than in water 
(pH 3.5) (Table 4); and the AUC of the corresponding 6’ß-hydroxylovastatin plus 
6’ß-hydroxylovastatin acid decreased to 12% in GFJ pretreated rats than 
pretreated in water (pH 3.5) (Table 5).  The AUC of lovastatin acid after 
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coadministration of lovastatin with GFJ in rats pretreated with GFJ (Group C) 
showed a 116% increase compared to pretreatment with water (pH 3.5).  The 
portal plasma AUC of lovastatin acid plus lovastatin (Group B) showed 22% 
increase in AUC in the GFJ pretreated rats than in water (pH 3.5).  The AUC of 
lovastatin acid plus lovastatin after coadministration of lovastatin with GFJ in rats 
pretreated with GFJ (Group C) showed an 82% increase compared to 
pretreatment with water (pH 3.5).  The AUC of the 6’ß-hydroxylovastatin and 6’ß-
hydroxylovastatin acid was 186 and 83.1 (Group B) and 181 and 77.0 nM*h 
(Group C), respectively.  The AUC of the oxidized products was not further 
reduced upon coadministration with GFJ (Group B vs. C). 
 
Effect of orally dosed GFJ on PK of lovastatin and enalapril after intravenous 
dosing   
 
The lovastatin acid and lovastatin plasma PK parameters following IV 
administration of lovastatin (2 mg/kg) to rats pretreated (-0.5 h) with water or GFJ 
(1:3 diluted) are shown in Table 6.  Similar PK data for enalapril are shown in 
Table 7.  The PK parameters did not change between the two pretreatment 
groups for both drugs. 
 
4.2 Discussion 
 
It is well known that GFJ inhibits the intestinal CYP3A4 (Schmiedlin-Ren et al. 
1997; He et al., 1998), and also the Pgp, MRP2 and OATP (Honda et.al, 2004, 
Dresser et al., 2002).  The literature is replete with examples of drug interactions 
with CYP3A (Saito et al., 2005).  For the first time, we demonstrate in this study, 
that GFJ also inhibits the esterase, specifically carboxylesterase (CE), activity in 
vitro in rats and humans and in vivo in rats.   Carboxylesterases are ubiquitous 
enzymes responsible for the metabolism of xeno- and endo-biotics (Williams et 
al., 1985). Though other fruit juices are shown to inhibit esterase activity, the 
literature lacks reports on esterase inhibition by GFJ.  This report provides the 
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proof of concept with the demonstration of inhibitory effect of GFJ on PNPA and 
the prodrugs lovastatin and enalapril using purified porcine esterase.  Lovastatin 
is known to be hydrolyzed by human carboxylesterase (hCE1/2) to its active acid 
form and to be oxidized by CYP3A (Halpin et al., 1993). A recent study (Chen et 
al., 2005) also suggested that lovastatin is a weak substrate of Pgp.  Thus, the 
modes of interaction of GFJ with lovastatin in vivo could be CYP3A inhibition, 
esterase inhibition, and or Pgp inhibition.   Enalapril, on the other hand, is a 
substrate only for carboxylesterase (hCE1) (Tocco et al., 1982; Drummer et al., 
1990).  The inhibition of hCE1 could lead to increased stability of esters in the gut 
enterocytes and lumen, resulting in greater absorption of esters, and hence 
higher exposure to the active acids, via rapid hydrolysis in plasma, for lovastatin 
and enalapril.   
 
Esterase inhibition in vitro 
  
The hydrolysis of these esters (measured by product formation) by purified 
porcine esterase was inhibited by GFJ in a concentration dependent manner 
(Figure 2).  GFJ significantly inhibited the hydrolysis of lovastatin and enalapril 
also in rat intestinal lumen, and rat and human intestinal and/or liver S9, as 
depicted in Figures 3 - 5.  The Caco-2 system was utilized to check if the 
increased stability of prodrugs in the gut by GFJ could lead to enhancement of 
the permeability.  Caco-2 cells used were determined to contain only a minor 
CYP3A activity, as indicated in Figure 6.   Thus, effects due to Pgp could be 
sorted out for lovastatin using this model.  GF120918, a Pgp and BCRP inhibitor 
(Xia et al., 2005), failed to significantly alter lovastatin permeability suggesting 
that the contribution of Pgp to lovastatin permeability was negligible.  GFJ led to 
enhancement of Aà B permeability of lovastatin and enalapril (Figures 8A and 
9A).  Thus, it is mainly the esterase inhibition attribute of GFJ that led to the 
higher permeability of lovastatin.  As expected, in these experiments the 
intracellularly trapped lovastatin acid and enalaprilat were reduced by GFJ 
(Figures 8B and 9B).  The amount of lovastatin acid and enalaprilat on the donor 
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side at the end of the incubation was very low and was not affected by GFJ.  The 
published in vitro and in vivo results (Morrison et al., 1986) indicate that enalapril 
is primarily absorbed by a non-saturable, passive diffusion process and it is not a 
suitable model compound for studying dipeptide transporter interaction in rats.  
Our data (Results section) confirmed that GFJ indeed did not affect the uptake of 
enalapril (Figures 10A and 10B).   
 
Esterase inhibition in vivo  
 
In vivo, the exposure to lovastatin acid was increased by 279%, 157% and 170% 
in rats following oral administration of lovastatin with 1:3 diluted, 1:2 diluted and 
concentrated GFJ, respectively, compared to dosing with water (pH 3.5) (Table 
2).  At higher concentrations of GFJ, however, a drop in exposure was observed.  
This is believed to be due to trapping/binding of the drug particles by GFJ pulp, 
which makes less of free drug available for absorption when higher strengths of 
GFJ are used.  This hypothesis was tested by spiking a constant amount of drug 
in GFJ of various strengths followed by mixing and centrifugation.  The 
concentration of the drug in the centrifugate (pulp free) was much lower at higher 
GFJ strengths, as suggested in Table 1, supporting our hypothesis.  BNPP, a 
known esterase inhibitor (Walker et al., 1983), produced an effect similar to GFJ 
(Tables 2).  The exposure to lovastatin acid was increased by 141% in rats 
following oral coadministration of lovastatin with BNPP compared to 
coadministration with water.  The positive BNPP effect suggested that the 
esterase plays a significant role in modulating the oral exposure to lovastatin.  
Thus, the large increase in AUC observed with GFJ was a combination of its 
effects due to CYP3A and esterase inhibition.  In order to differentiate the modes 
of GFJ effects via CYP3A inhibition and esterase inhibition, portal vein-
cannulated rats were pretreated with GFJ at -15 and -2 hr of lovastatin 
administration to achieve a maximal inactivation of CYP3A activity.  6’ß-
hydroxylovastatin, the major CYP3A-mediated metabolite (Vyas et al., 1990) and 
its hydroxy acid (6’ß-hydroxylovastatin acid) in portal plasma were determined to 
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qualitatively assess the magnitude of intestinal CYP3A activity involved.   The 
portal exposure of 6’ß-hydroxylovastatin and 6’ß-hydroxylovastatin acid was 
significantly decreased to ~11% (Figures 27A and 27B; Table 5), as expected, 
upon pretreatment with GFJ compared to the pretreatment with water.   As a 
result of inhibition of CYP3A by GFJ pretreatment, the portal plasma exposure to 
lovastatin acid was increased by 49% (Table. 4, Groups A and B).  When 
lovastatin was coadministered with GFJ (Group C) to portal vein cannulated rats 
pretreated with GFJ at -15 and -2 hr, the portal plasma exposure to CYP3A 
mediated products 6’ß-hydroxylovastatin and 6’ß-hydroxylovastatin acid was 
generally unchanged, compared to Group B rats, as shown in Table 5, indicating 
that the CYP3A activity remained inhibited by the pretreatment regimen.  
However, the portal plasma AUC of lovastatin acid in rats coadministered with 
GFJ (Group C) was further increased by 45% (Table 4).  The additional 45% 
exposure increase in Group C is postulated to be the results of inhibition of gut 
lumen and enterocyte esterase by the co-administered GFJ.  The quantitation of 
lovastatin plus lovastatin acid showed a similar trend.  Thus, both CYP3A 
inhibition and esterase inhibition attributes of GFJ led to the exposure increases 
for lovastatin and the active drug lovastatin acid in rats.   
 
The exposure to enalaprilat was similarly increased by 65 and 70% in rats 
following oral coadministration of enalapril with 1:3 and 1:2 diluted GFJ, 
compared to coadministration with water alone (Figure 25A, Table 3).  Enalapril 
is only metabolized by carboxylesterase (hCE1), and is not a CYP3A substrate, 
thus the esterase inhibition by GFJ led to oral exposure increase of enalaprilat in 
rats. This is consistent with the increased exposure of enalapril when 
coadministered with the esterase inhibitor BNPP (Table 2), as well as with the in 
vitro data.  When GFJ was administered orally 0.5 h prior to the IV administration 
of lovastatin and enalapril to rats the IV pharmacokinetic parameters remained 
unaltered, indicating that single oral administration of GFJ did not alter the 
esterase activity at the hepatic level. 
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5. CONCLUSIONS 
 
The current study, for the first time, demonstrated that GFJ decreased lovastatin 
and enalapril hydrolysis in the gut, and thereby markedly increased metabolic 
stability and permeability of esters, leading to the enhancement of exposure to 
lovastatin acid and enalaprilat in rats.  The esterase inhibition by GFJ similarly 
could also lead to oral exposure increase of lovastatin acid and enalaprilat in 
humans.  Moreover, it is proposed that other ester prodrugs are also likely to 
show drug interactions mediated via esterase inhibition attribute of GFJ in the 
clinic.    
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PART II 
 
ESTERASE INHIBITION BY GRAPEFRUIT JUICE FLAVONIDS LEADS TO A 
NEWLY IDENTIFIED DRUG INTERACTION 
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9. INTRODUCTION 
 
Since the first report of the GFJ effect on the oral bioavailability of felodipine 
(Bailey et al., 1989, 1991), many studies for identifying the active components 
responsible for the GFJ effects have been reported (Bailey et al., 1993, Edwards 
et al., 1996; Fukuda et al. 1997; Schmiedlin-Ren et al., 1997, He et al., 1998; 
Guo et al., 2000; Ho et al., 2001).  GFJ composition varies from variety to variety 
and from lot to lot and also depends on the preparation method (De Castro et al., 
2006).  In all cases, the majority of the constituents are flavonoids (Ho et al., 
2000). Naringin, a predominant constituent in GFJ, is present in concentrations 
up to 2000 µM (Ross et al., 2000). Even relatively low abundance 
flavonoids ,such as quercetin, occur  in the 20 µM range.  Bergamottin and 6’,7’-
dihydroxybergamottin, the most abundant furanocoumarin derivatives, are well 
studied GFJ constituents that are present in concentrations up to 40 µM 
(Edwards et al., 1996).  Although many bioflavonoids inhibit CYP3A in vitro (Ho 
et al., 2001), in vivo, naringin alone at concentrations found in GFJ was not 
capable of producing a clinical drug interaction such as seen with grapefruit juice 
(Bailey et al., 1998).  Several furanocoumarins in grapefruit juice are effective in 
vitro CYP3A inhibitors and are currently suggested to be clinically active 
constituents (Schmiedlin-Ren et al., 1997, He et al., 1998).   
 
In Part I, we demonstrated that GFJ inhibits esterase activity and mediates 
pharmacokinetic interaction with ester prodrugs lovastatin and enalapril, It is 
important to identify the active components responsible for this new esterase-
mediated GFJ effects in vivo.  Several classical esterase inhibitors are known 
including diethyl p-nitrophenyl phosphate (Walker et al., 1983) and bis-p-
nitrophenylphosphate (BNPP) (Gratzl et al., 1975).  However, the extreme toxicity 
of these compounds precludes their clinical use.  Recently, a series of 
synthesized benzene sulfonamides and the aromatic dione family were identified 
as selective inhibitors of CEs (Wadkins et al., 2004 and 2005).  Likewise, 
flavoring ester mixtures in strawberry juice were also reported to interact with the 
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prodrug of tenofovir leading to enhanced permeability across Caco-2 cells (Van 
Gelder et al., 2002).    In this study,  the esterase inhibition potential of ten 
grapefruit juice components towards PNPA hydrolysis as well as the effect of two 
selected components on the esterase mediated changes in the permeability in in 
vitro systems, and in in vivo rat exposure to active acids of enalapril and 
lovastatin upon coadministration are described. 
 
10. OBJECTIVES 
 
The objectives of this study were a) to identify grapefruit juice components 
responsible for the new esterase substrate-GFJ drug interactions, b) to evaluate 
esterase inhibition potential of the identified GFJ components (s) on hydrolysis of 
ester prodrugs enalapril and lovastatin by human liver microsomes, c) to evaluate 
effects of the identified constituent esterase inhibitor(s) on permeability of 
enalapril and lovastatin across Caco-2, d) to evaluate effects of the identified 
esterase inhibitor(s) on hydrolysis of enalapril and lovastatin in vitro in SD rats, e) 
to evaluate effects of the identified esterase inhibitor(s) on oral exposure of 
enalapril and lovastatin in SD rats in vivo, and f) to differentiate between CYP3A, 
esterases, and Pgp effects of the identified active components. 
   
11. MATERIALS AND METHODS  
 
11.1 Materials   
 
Enalapril, lovastatin, para-nitrophenyl acetate (PNPA), p-nitrophenol, 
phenylmethylsulfonyl fluoride (PMSF), bis-p-nitrophenylphosphate (BNPP), 
bergapten, kaempferol, quercetin, morin, galangin, naringenin, naringin, and 
hesperidin were purchased from Sigma (St. Louis, MO); bergamottin and 6’,7’-
dihydroxybergamottin (6’,7’-DHB) were purchased from BD Gentest (Woburn, 
MA); enalaprilat and lovastatin hydroxy acid were purchased from Toronto 
Research Chemicals Inc. (North York, ON).  Human liver microsomes (pool of 50 
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donors) were purchased from Xenotech (Lenexa, KS); and purified porcine 
esterase was purchased from Sigma (St. Louis, MO). 
 
11.2 Effect of GFJ chemical constituents on purified porcine esterases 
 
Purified porcine liver esterase (5 munit/mL) in 0.1 M potassium phosphate buffer 
pH 7.4 was incubated at 370C with PNPA (667 µM) and one of the ten GFJ 
components at ten different concentrations; bergamottin (0~100 µM), bergapten 
(0~ 100 µM),  6’,7’-dihydroxybergamottin (0 ~ 100 µM), kaempferol (0 ~ 50 µM), 
quercetin (0 ~ 50 µM), morin (0 ~ 50 µM), galangin (0 ~ 50 µM), naringenin (0 ~ 
200 µM), hesperidin (0 ~ 200 µM), and naringin (0 ~ 1000 µM).  Their structures 
are shown in Figure 53.  The highest concentration of each component used for 
esterase inhibition evaluation varied based on their solubility in incubation buffer 
and their concentration found in GFJ.  The formation of the product, para-
nitrophenol, was monitored spectrophotometrically at 405 nm at 2 min.  BNPP 
(0~ 20µM) was used as a positive control. 
 
11.3 Effect of GFJ chemical constituents on esterases in human liver microsmes 
 
Hydrolysis of PNPA by human liver microsomes 
 
Human liver microsomes at 0.25, and 0.5, and 1.0 mg/mL were incubated at 
room temperature with 0.67 mM para-nitrophenylacetate in phosphate buffer (pH, 
7.4) in a final volume of 100 µL.  The formation of product, para-nitrophenol, was 
monitored spectrophotometrically at 405 nm for 0, 1, 2, 3, and 4 min. The results 
are summarized in Figure 28.  
 
Effect on esterase activity in human liver microsomes  
 Human liver microsomes (0.1 mg/mL) were incubated at room temperature with 
0.67 mM PNPA in phosphate buffer (pH, 7.4) and one of the ten GFJ 
components at ten different concentrations as described in the section above.   
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The formation of product para-nitrophenol was monitored spectrophotometrically 
at 405 nm at 2 min. 
 
11.4 Effect of GFJ chemical constituents on A-to-B permeability of lovastatin and  
enalapril across Caco-2 membrane  
 
Caco-2 cell cultures were prepared as described in Part I, section 2.3.  Single 
directional transport studies were performed at 37°C in air.  Prior to each 
experiment, the confluent cell monolayer on TranswellTM inserts were washed  
and equilibrated for 30 min with transport medium [Hanks' balanced salt solution 
containing 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) 
and 10 mM glucose, pH 7.4].  The experiment was initiated by adding a solution 
of lovastatin in the transport medium at pH 7.0 or enalapril in the transport 
medium at pH 6.0, containing various amount of grapefruit components  to the 
apical compartment.  Both lovastatin stock solution in the donor side and buffer in 
the receiver side contained GF120918 (2 µM final concentrations in the 
incubation)  to assess Pgp effect on lovastatin permeability.  At 15, 30, 45, and  60 
min, aliquots were withdrawn from the basolateral side and replaced immediately 
with an equal amount of fresh transport media, except at the  60-min time point 
(the end of the incubation).  After the permeability studies described in the 
previous section, TEER values were measured again to assure the integrity of 
the cells.  The cells were washed three times with cold transport medium and 
then were lysed with 1% acetic acid in water.  The cell lysates were extracted 
with acetonitrile containing carbutamide as internal standard and centrifuged at 
3000xg for 10 min.  The supernatants were collected and analyzed using 
LC/MS/MS.  
   
11.5 Pharmacokinetic studies 
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Pharmacokinetics experiments with enalapril and lovastatin were performed in 
male Sprague-Dawley rats (n=3 or 4, each group) (Hilltop Laboratory, PA) 
weighting 280 to 350 g implanted with either jugular vein cannula or both jugular 
and portal vein cannulas.  Animals were fasted overnight and for the duration of 
the study.  Water was provided ad libitum.  
For systemic exposure studies, jugular vein cannulated rats were orally dosed by 
gavage with enalapril and lovastatin (10 mg/kg, 10 ml//kg) in (a) water, (b) 
kaemferol (2 and 10 mg/kg); and (C) naringenin (2 and 10 mg/kg).   Venous 
blood samples (0.3 mL) were collected from jugular vein catheters (JVC) into 
heparin tubes containing 3 µL of 200 mM PMSF and 5 µL of acetic acid (6:4 
diluted with water) predose and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h postdose.  
Samples were centrifuged and plasma samples were collected and frozen at -
80ºC until analyzed. 
For portal exposure studies, portal vein cannulated (PVC) rats orally dosed by 
gavage with lovastatin (10 mg/kg, 10 ml//kg) formulated in (a) water and (b) 
kaempferol (10 mg/kg).  Portal blood samples (0.3 mL) were collected into 
heparin tubes containing 3 µL of 200 mM PMSF and 5 µL of acetic acid (6:4 
diluted with water) predose and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h postdose.  
Samples were centrifuged and plasma samples were collected and frozen at -
80ºC until analyzed. 
LC/MS/MS Analysis 
 
 In vivo plasma samples were protein precipitated and analyzed with an 
LC/MS/MS method.   Blank plasma, in which esterase was inactivated with 1% 
acetic acid and 2 mM PMSF was used to construct plasma standard curves.  In 
general, to one volume of plasma, were added 3 volumes of acetonitrile 
containing carbutamide (0.2 µM) as the internal standard.  Samples were 
vortexed and then centrifuged for 15 min at 3000 g.  Half of the supernatant was 
dried down under nitrogen, and reconstituted with 150 µL of 5% acetonitrle in 
0.1% formic acid.  The LC/MS/MS system consisted of a binary high 
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performance liquid chromatography pump (1100; Agilent Technologies, Palo Alto, 
CA), an HTS PAL autosampler (LEAP Technologies, Carrboro, NC), and a triple-
quadrupole mass spectrometer (API-4000; Applied Biosystems, Foster City, CA).  
Separation was performed on an YMC-ODS-AQ C18 column (30 mm ´ 2.0 mm; 
Waters, Milford, MA) using mixtures of formic acid (0.1%) in water and  
acetonitrile as a mobile phase.  The mass spectrometer was operated in the 
multiple reaction monitoring mode (MRM) using positive ion electrospray 
ionization. MRM was set at m/z 405.3 ?  285.3 for Lovastatin, 423.3 ?  303.4 for 
lovastatin acid, 421.4 ?  283.4 for 6’ß-hydroxylovastatin, 377.1 ?  233.9 for 
enalapril, 349.3 ?  206.4 for enalaprilat and m/z 272.4 ?  156.2 for carbutamide 
(internal standard). The concentration range of standard curves for enalapril, 
enalaprilat, lovastatin and lovastatin acid, respectively was generally between 1 
to 2500 nM with 12 points, and the  quantification limit for enalapril, enalaprilat, 
lovastatin and lovastatin acid was generally 2 nM. 
 
Data Analysis 
 
Percent inhibition of PNPA hydrolysis for each inhibitor was calculated as the 
ratio of OD at each concentration of inhibitor with respect to that in the absence 
of the inhibitor, and the percentages were plotted against the concentrations of 
each tested inhibitor using Prism software (GraphPad, San Diego, CA).  The 
sigmoidal dose-response (variable slope) model was used to determine the 
concentration which gave 50% inhibition (IC 50).  The IC50 was calculated using 
the equation  
Y = Minimum activity + (Maximum activity - Minimum activity)/(1 + 10e(LogEC50-
X)*HillSlope)) 
where X is the logarithm of concentration, and Y is the percent activity. 
 
 29 
PK parameters were calculated by noncompartmental analysis WinNonlin 
software Version 5.1 (Pharsight, Mountain view, CA). Statistical analysis was 
using student t test.     
 
12. RESULTS AND DISCUSSIONS 
 
12.1 Results 
 
Kinetics of PNPA hydrolysis by human liver microsomes 
 
At PNPA concentrations up to 0.68 mM, the formation of para-nitrophenol was 
linear up to 2 minutes incubation at protein concentrations of 0.025, 0.05, and 0.1 
mg/mL, respectively.  
 
Effect of GFJ chemical components on purified porcine esterases 
 
The inhibition curves of ten GFJ components and BNPP on purified porcine 
esterases are shown in Figures 29-32. Their inhibitory potential towards esterase 
activity varied widely (Table 8).  Bergamottin, 6’,7’-DHB and bergapten (each at 
100 µM), hesperidin at 200 µM, and naringin at 1000 µM did not show 
appreciable inhibition of the hydrolysis of PNPA by porcine liver esterase.  
However, morin, galangin, kaempferol, quercetin, and naringenin all showed an 
inhibitory effect.  Estimates of IC 50 were 1.8 µM for morin, 2.8 µM for galangin, 
5.1 µM for kaempferol, 5.9 µM for quercetin, and 110 µM for naringenin.   The 
value of IC50 for BNPP was 1.1 µM. 
 
Effect of GFJ chemical components on PNPA hydrolysis by human liver 
microsomes   
 
The inhibition curves of ten GFJ components and BNPP on PNPA hydrolysis in 
human liver microsomes are shown in Figures 33-36.   Likewise, in human liver 
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microsomes bergamottin, 6’,7’-DHB, bergapten, naringin and hesperidin did not 
appreciably inhibit the hydrolysis of PNPA (Table 9).  Estimates of IC 50 for human 
liver microsomes were 80 µM for morin, 81 µM for galangin, 62 µM for 
kaempferol, 43 µM for quercetin, 30 µM for naringenin. The value of IC50 for 
BNPP was 11.9 µM. 
 
Effect of kaempferol and naringenin on A-to-B permeability in Caco-2 cells 
 
The permeability of lovastatin was not altered by GF120918, a Pgp and BCRP 
inhibitor, and was increased by 65%, 64%, and 66% by kaempferol (250 µM), 
naringenin (250 µM), and the mixture of kaempferol (250 µM) and GF120918 (2 
µM; Figure 37A).   In Caco-2 cells at 1 hr the intracellularly trapped lovastatin 
was not significantly altered, with the respective values of 117%, 96%, 105%, 
and 116% of the control, whereas the trapped amount of lovastatin acid was 
unaffected by GF120918 and decreased to 55%, 29%, and 52% by kaempferol, 
naringenin, and mixture of kaempferol and GF120918.   The overall ratios of 
lovastatin acid to lovastatin in Caco-2 cells were decreased and are shown in 
Figure 37B.  The permeability of enalapril was increased by 106%, 79%, 188%, 
and 219% with kaempferol (50 and 250 µM) and naringenin (50 and 250 µM), 
respectively (Figure 38A).  The corresponding intracellularly trapped enalapril in 
Caco-2 cells at 1 hr was increased by 67%, 69%, 26 %, and decreased 11%; and 
enalaprilat was decreased to 55, 37, 58, and 40%.  The overall ratios of 
enalaprilat to enalapril were decreased and are shown in Figure 38B.  The 
amount of lovastatin acid and enalaprilat on the donor side at the end of the 
incubation was very low and was not affected by kaempferol and naringenin.  
 
Effect of kaempferol and naringenin on oral PK of enalaprilat in rats 
 
The plasma concentration-time profiles of enalaprilat in rats following oral co-
administration of enalapril (10 mg/kg) with water, kaempferol (2 and 10 mg/kg), 
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and naringenin (2 and 10 mg/kg) are shown in Figures 39A and 39B.  The PK 
data are shown in Table 10.   
 
Effect of kaempferol and naringenin on oral PK of lovastatin acid in rats  
 
 The plasma concentration-time profiles of lovastatin acid in rats following oral 
co-administration of lovastatin (10 mg/kg) with water, kaempferol (2 and 10 
mg/kg), and naringenin (2 and 10 mg/kg) are shown in Figures 40A and 40B.  
The PK data are shown in Table 11.   
 
Effect of kaempferol on the portal plasma PK of lovastatin 
 
 The portal vein plasma concentration-time profiles of lovastatin, lovastatin acid, 
and the major oxidative product, 6’ß-hydroxylovastatin, following oral co-
administration of lovastatin (10 mg/kg) to rats with water or kaempferol (10 mg/kg) 
are shown in Figures 41A, B, and C.  The 6’ß-hydroxylovastatin was identified by 
LC/MS/MS spectral comparison with published data (Halpin et al., 1993), and 
quantitated in plasma using lovastatin standard curves. The portal plasma PK 
parameters are shown in Table 12.  The AUC ratio of 6’ß-hydroxylovastatin and 
lovastatin was 0.064 and 0.078 to rats upon coadministration of lovastatin with 
water and kaempferol, respectively. 
 
12.2. Discussions 
 
Esterase inhibition in vitro   
 
The ten grapefruit juice chemical components investigated in this study belong to 
two major and widely known classes, flavonoids (aglycones and glycosides) and 
furanocoumarins.  In the earlier years, grapefruit flavonoids were extensively 
studied for CYP3A inhibition potential to better understand the GFJ effect on oral 
availability of CYP3A substrates. Though these flavonoids in vitro inhibited 
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CYP3A4 but did not reproduce the grapefruit juice effect when administered 
orally (Rashid et al. 1993, Bailey et al. 1993). Currently, it is believed that 
grapefruit furanocoumarins, bergamottin and 6’,7’-dihydroxybergamottin in GFJ 
are responsible for the GFJ interaction by competitive and mechanism-based 
inhibition of CYP3A in the small intestine.  These two potent CYP3A inhibitors, in 
the current study, were found to be devoid of esterase inhibitory activity at 100 
µM, a concentration higher than that found with GFJ.  Some of the flavonoids on 
the other hand were found to have esterase inhibitory activity.  The effect of 
flavonoids in aglycone form on carboxylesterases is distinguishably different from 
flavonoids in glycoside form.  Naringin and hesperidin, the two glycosidic 
flavonoids, did not inhibit PNPA hydrolysis at concentrations found in GFJ. 
However, the five flavonoids morin, galangin, kaempferol, quercetin, and 
naringenin, in aglycone forms, markedly inhibited PNPA hydrolysis with IC50 
values in the low µM range, 1.8 to 110 µM.  The combined effects of flavonoids 
could contribute significantly to the GFJ effects on PK of ester prodrugs.  The 
effect of kaempferol and naringenin on enalapril and lovastatin permeability in 
Caco-2 model and PK in rats was examined.  Kaempferol was reported to inhibit 
CYP3A and Pgp in vitro (Jignesh et al., 2004); Caco-2 cells used in our study 
were determined to contain only a minor CYP3A activity (Figure 6).  Thus, effects 
due to Pgp could be sorted out readily for lovastatin, a prodrug metabolized by 
CYP3A as well as carboxylesterase, using this model.  Kaempferol and 
naringenin led to enhancement of Aà  B permeability of lovastatin and enalapril 
(Figures 37A and 38A).  GF120918, a Pgp and BCRP inhibitor (Xia et al., 2005), 
failed to significantly alter lovastatin permeability suggesting that the contribution 
of Pgp to lovastatin’s permeability was negligible.  Thus, it is mainly the esterase 
inhibition attribute of kaempferol and naringenin that led to the higher 
permeability of lovastatin and enalapril.  As expected, in these experiments the 
intracellularly trapped lovastatin acid and enalaprilat were reduced by kaempferol 
and naringenin, as indicated by decreases in the ratios of lovastatin acid to 
lovastatin to 59%, 27% and 45% by kaempferol, naringenin and a mixture of 
kaempferol and GF120918 (Figure 37B), and enalaprilat to enalapril to 27%, 19%, 
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44% and 38% by kaempferol (50 and 250 µM) and naringenin (50 and 250 µM), 
respectively (Figures 38B).   
 
Esterase inhibition in vivo   
 
The AUC of lovastatin acid was increased by 171%, 246%, 159%, and 288% in 
rats following oral administration of lovastatin with kaempferol (2 and 10 mg/kg) 
and naringenin (2 and 10 mg/kg), respectively, compared to dosing with water 
(Table 11).  BNPP, a known esterase inhibitor (Walker et al., 1983), produced an 
effect similar to kaempferol and naringenin, as described in Part I.  The positive 
BNPP effect suggested that the esterase plays a significant role in modulating 
the oral exposure to lovastatin.  Thus, the large increase in AUC observed with 
kaempferol and naringenin was a combination of their effects due to CYP3A and 
esterase inhibition.  In order to differentiate the modes of kaempferol and 
naringenin effects via CYP3A inhibition, esterase inhibition, and/or combination 
of both, portal vein-cannulated rats were dosed with water or with kaempferol (10 
mg/kg).  The portal plasma exposure of lovastatin acid, lovastatin, and 6’ß-
hydroxylovastatin with kaempferol showed 113%, 154%, and 208% higher AUC 
than dosing with water.  Lovastatin is known to be metabolized by CYP3A to 6’ß-
hydroxylovastatin as one of the major oxidized products (Halpin et al., 1993).   
The possible effect of kaempferol on lovastatin exposure by inhibiting intestinal 
CYP3A was examined by comparing AUC ratio of oxidized metabolite 6’ß-
hydroxylovastatin to lovastatin. The 6’ß-hydroxylovastatin was identified by 
LC/MS/MS spectral comparison with the published data (Halpin et al., 1993), and 
quantitated in plasma using lovastatin standard curves.  The AUC ratio of 6’ß-
hydroxylovastatin to lovastatin was 0.064 and 0.078 for coadministration with 
water and kaempferol, respectively (Table 12) indicating that kaempferol did not 
markedly inhibit intestinal CYP3A activity in rats.  This finding is consistent with 
the literature that kaempferol and naringenin are weak CYP3A inhibitors with IC50 
values greater than 100 µM (Ho et al., 2001).   
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The exposure to enalaprilat was also increased by 60%, 109%, 18%, and 38% in 
rats following oral administration of enalapril with kaempferol (2 and 10 mg/kg) 
and naringenin (2 and 10 mg/kg), respectively, compared to dosing with water 
(Figures 39A and 39B, Table 10).  Enalapril is only metabolized by 
carboxylesterase (hCE1), and is not a CYP3A substrate, thus the esterase 
inhibition by kaempferol and naringenin largely led to oral exposure increase of 
enalaprilat in rats. This is consistent with the increased exposure of enalapril 
when coadministered with the esterase inhibitor BNPP, as seen in Part I, as well 
as with the in vitro data. 
 
13. CONCUSIONS 
 
This study identified GFJ flavonoids as esterase inhibitors, and these flavonoids 
maybe the active components responsible for esterase inhibitory activity of GFJ.  
Two of the flavonoids kaempferol and naringenin showed significant exposure 
changes to the active acids in rats when coadministered with lovastatin and 
enalapril.    These flavonoids have the potential of being used clinically as boost 
agents to selectively inhibit esterase for enhancing the absorption of ester 
prodrugs. 
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THE INTERACTION MECHANISM OF GRAPEFRUIT JUICE CHEMICAL 
CONSTITUENTS WITH ESTERASES 
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14. INTRODUCTION 
 
Several classical esterase inhibitors are known in the literature, including diethyl 
p-nitrophenyl phosphate (paraxon) (Walker et al., 1983), and bis-p-
nitrophenylphosphate (Gratzl et al., 1975) (BNPP). Recently, a series of benzene 
sulfonamides were identified as selective inhibitors of human carboxylesterase 
(hCEs), and the aromatic dione family (Wadkins et al., 2004 and 2005).  These 
esterase inhibitors vary structurally and act differently. In this study Part II, we 
demonstrated that GFJ flavonoids were carboxylestserase inhibitors.  In this 
study, we want to further examine the mechanism of this new action of GFJ 
flavonoids.  Ideally, the pure human esterases would be used; however, because 
pure human carboxyl esterases are not commercially available, the available 
purified porcine esterases were used as a model of the human enzyme instead.  
The hydrolysis of enalapril, a prodrug for the treatment of hypertension, is known 
to be predominantly mediated by human carboxylesterase I (hCE1), and  the 
hydrolysis of CPT11, a carboxylic ester prodrug on the market for first line 
therapy of patients with advanced coloretal cancer, was dominantly mediated by 
human carboxyl esterase II (hCE2) (Humerickhouse et al., 2000).  Therefore, 
CPT11 and enalapril, the selective hCEs substrates, were selected as the model 
compounds in this study. 
 
15. OBJECTIVE 
 
The objective of this study was to evaluate the interaction mechanism of GFJ 
flavonoids with esterases. 
 
16. METHODS 
 
16.1 Hydrolysis of CPT11 
 
Chemical hydrolysis 
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Studies on the chemical hydrolysis of CPT11 were performed in 0.1 M phosphate 
buffer, pH 3.5, 7.0 and 7.4 respectively.  CPT11 (5 µM) was incubated in 0.1 M 
phosphate buffer with pH 3.5, 7.0 and 7.4, respectively.  At 0, 15, 30, and 60 min, 
reactions were stopped by adding an equal volume of acetonitrile containing 
carbutamide as the internal standard.  The samples were directly analyzed with 
LC/MS/MS for the amount of CPT11 and SN38. 
 
Hydrolysis in purified porcine esterase 
Studies on the hydrolysis of CPT11 by purified porcine esterase were performed.  
Purified porcine esterase (0.1 unit/mI) in 0.1 M potassium phosphate buffer, pH 
7.4) were incubated with CPT11 (1.0, 2.0, 4.0, 8.0, 16.0, 32 µM) in 96-well plates.  
Reactions were initiated by addition of CPT11 in 0.1 M potassium phosphate 
buffer, pH 7.4 containing < 0.2 % DMSO, and were carried out for 10 minutes at 
37oC.  Reactions were stopped by the addition of acetonitrile (1:1. v:v) containing 
carbutamide as the internal standard.  The plates were stored at 4oC for 30 
minutes, and then centrifuged in order to pellet the precipitated proteins.  The 
supernatants were analyzed by LC/MS/MS for relative amounts of SN38.   
Hydrolysis in human liver microsomes and S9 fractions   
 
Studies on the hydrolysis of CPT11 by human liver S9 and microsomes were 
performed. Human liver microsomes and S9 (1 mg/mL in 0.1 M potassium 
phosphate buffer, pH 7.4) were incubated with CPT11 (0, 0.125, 0.25, 0.5, 1.0, 
2.0, 4.0, 8.0, 16.0 µM) in 96-well plates.  Reactions were initiated by addition of 
CPT11 in 0.1M potassium phosphate buffer, pH 7.4 containing < 0.2 % DMSO, 
and were carried out for 30 minutes at 37oC.  Reactions were stopped by 
addition of acetonitrile (1:1  v:v) containing carbutamide as the internal standard.  
The samples were processed and  analyzed as described above. 
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16.2 Hydrolysis of enalapril 
 
Chemical hydrolysis 
Studies on the chemical hydrolysis of enalapril were performed.   Enalapril (5 µM) 
was incubated at 37oC in 0.1 M phosphate buffer pH 4.5, 7.4 and 8.0, 
respectively.  At 0, 15, 80, and 240 min, an equal volume of acetonitrile 
containing carbutamide as the internal standard was added into the incubation 
mixtures.  The samples were directly analyzed with LC/MS/MS for enalapril and 
enalaprilat. 
 
Hydrolysis by purified porcine esterase 
 
Studies on the hydrolysis of enalapril by purified porcine esterase were 
performed.   Purified porcine esterases 0.025 unit/mL in 0.1 M potassium 
phosphate buffer (pH 7.4) were incubated with enalapril (0, 15.6, 31.2, 62.5, 125, 
250) in 96-well plates.  Reactions were initiated by addition of enalapril in 0.1M 
potassium phosphate buffer, pH 7.4 containing < 0.2 % DMSO, and were carried 
out for 10 minutes at 37oC.  Reactions were stopped by addition of acetonitrile 
(1:1, v:v) containing carbutamide as the internal standard.  The samples were 
stored at 4oC for 30 minutes, and then centrifuged in order to pellet the 
precipitated proteins.  The supernatants were diluted 10-fold using water, and 
then were analyzed by LC/MS/MS for relative amounts of enalaprilat.  
 
Hydrolysis by human liver microsomes or S9 fractions 
 
Studies on the hydrolysis of enalapril by human liver S9 and microsomes were 
performed.   Human liver microsomes and S9 (1 mg/mL in 0.1 M potassium 
phosphate buffer, pH 7.4) were incubated with enalapril (0, 15.6, 31.2, 62.5, 125, 
250) in 96-well plates.  Reactions were initiated by addition of Enalapril in 0.1M 
potassium phosphate buffer, pH 7.4 containing < 0.2 % DMSO, and  were carried 
out for 10 minutes at 37oC.  Reactions were stopped by addition of acetonitrile 
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(1:1, v:v) containing carbutamide as the internal standard.  The samples were 
processed and analyzed as described above. 
 
Inhibition studies   
 
The inhibition mechanism of naringenin on hydrolysis of CPT11 by purified 
porcine esterase was investigated.  Purified porcine esterase (0.1unit/mL) in 0.1 
M potassium phosphate buffer pH 7.4 were incubated at 37 oC with CPT11 of 
concentrations (1, 2, 4, 8, 16, 32 µM) and one of the five concentrations (0, 15.6, 
31.2, 62.5, 125, 250) of naringenin.   Reactions were initiated with the addition of 
purified porcine esterase.  After 10 min, reactions were stopped by addition of 
1% acetic acid in acetonitrile (1:1, v:v) containing carbutamide as the internal 
standard.  The sample plates were stored at 4 0C for 30 minutes, and then 
centrifuged in order to pellet the precipitated proteins.  The supernatants were 
analyzed by LC/MS/MS for relative amounts of SN38.   
 
The inhibition mechanism of kaempferol and quercetin on hydrolysis of CPT11 by 
purified porcine esterase was investigated.  Purified porcine esterase (0.1unit/mL) 
in 0.1 M potassium phosphate buffer pH 7.4 were incubated at 37 oC with CPT11 
of concentrations (1, 2, 4, 8, 16, 32 µM) and one of the five concentrations (0, 
0.13, 0.25, 0.5, 1, 2 µM) of kaempferol and quercetin.   Reactions were initiated 
with the addition of CPT11.  After 10 min, reactions were stopped by addition of 
acetonitrile (1:1, v:v) containing carbutamide as the internal standard.  The 
samples were analyzed as described above. 
 
The inhibition mechanism of naringenin on hydrolysis of enalapril by purified 
porcine esterase was investigated.  Purified porcine esterase (0.025 unit/mL) in 
0.1 M potassium phosphate buffer pH 7.4 were incubated at 37 oC with enalapril 
of concentrations (5, 10, 25, 50, 100, 250 µM) and one of the five concentrations 
(0, 15.6, 31.3, 62.5, 125, 250) of naringenin.   Reactions were initiated with the 
addition of enalapril.  After 10 min, reactions were stopped by addition of 
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acetonitrile (1:1, v:v) containing carbutamide as the internal standard.  The 
samples were processed and analyzed as described above. 
  
The inhibition mechanism of kaempferol and quercetin on hydrolysis of enalapril 
by purified porcine esterase was investigated.  Purified porcine esterase (0.025 
unit/mL) in 0.1 M potassium phosphate buffer pH 7.4 were incubated at 37 oC 
with enalapril of concentrations (5, 10, 25, 50, 100, 250 µM) and one of the five 
concentrations (0, 0.13, 0.25, 0.5, 1, 2 µM) of kaempferol and quercetin.   
Reactions were initiated with the addition of enalapril.  After 10 min, reactions 
were stopped by addition of acetonitrile (1:1, v: v) containing carbutamide as the 
internal standard.  The samples were processed and analyzed as described 
above. 
 
LC/MS Analysis  
 
The LC/MS method for enalaprilt analysis was described in Part I and II.  SN38 
and CPT11 were also analyzed with an LC/MS method .   The LC/MS/MS system 
consisted of a binary high performance liquid chromatography pump (1100; 
Agilent Technologies, Palo Alto, CA), an HTS PAL autosampler (LEAP 
Technologies, Carrboro, NC), and a triple-quadrupole mass spectrometer (API-
4000; Applied Biosystems, Foster City, CA).  Separation was performed on an 
YMC-ODS-AQ C18 column (30 mm ´ 2.0 mm; Waters, Milford, MA) using 
mixtures of formic acid (0.1%) in water and acetonitrile as a mobile phase .  The 
mass spectrometer was operated in the multiple reactions monitoring mode 
(MRM) using positive ion electrospray ionization. MRM was set at m/z 587.4 ?  
124.4 for CPT11 and 587.4 ?  124.4 for SN38.   The quantification limit for 
CPT11 and SN38 was generally 2 nM. 
 
Data analysis 
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Inhibition mechanism.  Direct plot, Lineweaver-Burk plot, and Eadie-Hofstee plot 
were used to evaluate inhibition mechanism. 
 
Ki Determination.  A non-simultaneous, nonlinear regression analysis was 
employed.  Each of the six independent experimental sets (control and each of 
the five inhibitor concentrations) was fit individually by non-linear regression to 
the Michaelis-Menten expression using Prism software (GraphPad, San Diego, 
CA).  Estimates of Ki were obtained from the linear regression plot of KM,app/Vmax 
as a function of the inhibitor concentration. The method for Ki determination is 
described by Copeland et al., 1996. 
 
17. RESULTS AND DISCUSSIONS  
 
17.1 Results 
 
CPT-11 hydrolysis by purified porcine esterase, and the effect of kaempferol, 
quercetin,and naringenin 
 
Less than 0.1 percent of the total CPT11 was hydrolyzed to SN38 in phosphate 
buffer pH 7.4 (Figure 42A), thus non-enzyme mediated hydrolysis was negligible.  
All three flavones, kaempferol, quercetin and naringenin, showed inhibitory 
effects on CPT11 hydrolysis by purified porcine esterases.  Kaempferol showed 
potent inhibitory effects on CPT11 hydrolysis (SN38 formation). The inhibition 
observed occurred over a broad range of substrate and inhibitor concentrations.  
Lineweaver-Burk plot for SN38 formation revealed common intercepts at the 
ordinate consistent with competitive inhibition.  Representative graph for 
kaempferol is presented in Figure 45B. The direct plot is presented in Figure 45A 
and the values of Vmax and Km from direct plot are summarized in Table 13.  
Kaempferol did not affect V max but significantly reduce Km suggesting competitive 
inhibition, consistent with the Lineweaver-Burk plot.  As with kaempferol, the 
inhibition by quercetin and naringenin occurred over a broad range of substrate 
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and inhibitor concentrations. Representative graphs for quercetin and naringenin 
are presented in Figures 46A and 47A and Figures 46B, 47B, respectively, 
values of apparent Vmax and Km of CPT11 are summarized in Table 13.  Primary 
Lineweaver-Burk plots showed a common intercept at the y-axis.  The 
mechanism of inhibition by both compounds is competitive.  By non-simultaneous, 
nonlinear regression analysis using the competitive model, estimates of the 
mean Ki for purified porcine liver esterase (Table 15) were 0.102 µM, 0.752 µM, 
and 55.4 µM for kaempferol, quercetin, and naringenin, respectively.   
 
Enlapril hydrolysis by purified porcine esterase, and the effect of kaempferol, 
quercetin,and naringenin 
 
Less than 0.2 percent of the total enalapril was hydrolyzed to enalaprilat in 
phosphate buffer pH 7.4 (Figure 42B), thus non-enzyme mediated hydrolysis was 
negligible.  Kaempferol, quercetin, and naringenin also showed inhibitory effects 
on hydrolysis of enalapril by purified porcine esterase. Eadie-Hofstee plots of 
kaempferol, quercetin, and naringenin inhibition are presented Figures 48B, 49B, 
and 50B.  Eadie-Hofstee plots of kaempferol, quercetin, and naringenin esterase 
inhibition were best described to be parallel lines suggesting that the mechanism 
of esterase inhibition by the three flavonids was noncompetitive inhibition. The 
direct plots of kaempferol, quercetin, and naringenin inhibition are presented in 
Figures 48A, 49A, and 50A; and the values of their apparent Vmax and Km were 
summarized in Table 14.   Kaempferol, quercetin, and naringenin did not affect 
Km of enalapril hydrolysis but significantly reduce the Vmax suggesting 
noncompetitive inhibition, consistent with the results obtained from Eadie-Hofstee 
plots.   
 
17. 2 Discussion 
 
Known carboxyl esterase inhibitors vary widely in size and structure, a class 
belonging to aromatic diones being prototypical inhibitors (Wadkins et.al, 2005).  
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These compounds acted as partially competitive reversible inhibitors, with the 
serine of esterase binding to the carbonyl carbon of the dione via a nucleophilic 
attack.  A series of benzene sulfonamides were identified as specific inhibitors for 
hCE2.  As with the aromatic dione family, these compounds act as partially 
competitive, reversible inhibitors (Wadkins et al, 2004). Flavonoids are inhibiting 
phosphodiesterase (Peluso MR, 2006), however, this study demonstrated 
flavonoids inhibited carboxylesterases. Three GFJ flavonoids were competitive 
inhibitors for CTP11 hydrolysis and noncompetitive inhibitors for enalapril 
hydrolysis.  As shown in Table 15, kaempferol appeared to be a much more 
potent carboxyl esterase inhibitor than naringenin.  The Ki value is 0.1 µM for 
kaempferol, and 55.4 µM for naringenin, a >500-fold difference.  However, 
structurally, the only difference between kaempferol and naringenin is the extra 
enol group in Ring-B. The enol group can undergo tautomerization to the keto 
form (a dione), making the carbonyl carbon more electropositive and facilitating  
nucleophilic attack by serine of esterase on the carbonyl carbon.  It is also 
interesting to note that the inhibition potential of flavonoid aglycones and 
flavonoid glycosides is different from each other.   
 
 
18. CONCLUSIONS 
 
This study showed that kaempferol, quercetin, and naringenin competitively 
inhibited hydrolysis of CPT11 (to SN38) and noncompetitively inhibited hydrolysis 
of enalapril (to enalaprilat).   
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SUMMARY 
 
This report describes a newly identified potential of GFJ in mediating 
pharmacokinetic drug drug interactions due to its capability of esterase inhibition.  
 
First, we demonstrate that GFJ inhibits purified porcine esterase activity towards 
p-nitrophenylacetate and the prodrugs lovastatin and enalapril.  In rat and human 
hepatic or gut S9 fractions and rat gut lumen GFJ inhibited the hydrolysis of 
enalapril and lovastatin, which are known to be metabolized principally by 
esterases, with lovastatin metabolized also by CYP3A.  In Caco-2 cells, with 
minimal CYP3A activity, permeability of these prodrugs was increased in the 
presence of GFJ.  In rats, oral coadministration of GFJ or an esterase inhibitor 
bis-(p-nitrophenylphosphate) with the prodrugs led to respective increases in 
plasma AUC by 70% or 57% for enalaprilat and 279% or 141% for lovastatin acid.   
Additionally, portal vein cannulated rats pretreated with GFJ at -15 and -2 hr prior 
to lovastatin administration (10 mg/kg PO) as a solution (a) in water showed 49% 
increase (CYP3A inhibited), and (b) in GFJ showed 116% increase (both CYP3A 
and gut esterase inhibited) in the portal plasma exposure to the active acid, 
compared to a non-GFJ pretreatment group.  Overall, along with the CYP3A 
inactivation, the decreased esterase activity also played a significant role in 
increasing the metabolic stability and permeability of esters by GFJ leading to 
enhancement of exposure to the active drugs in rats.  These new esterase 
inhibition findings indicate that the potential of DDIs between ester prodrugs and 
GFJ should also be considered in the clinic. 
 
We also explored ingredients of GFJ responsible for this new GFJ-prodrug 
interaction. The esterase inhibitory potential of ten constitutive  flavonoids and 
furanocoumarins were investigated towards para-nitrophenylacetate (PNPA) 
hydrolysis.  The furanocoumarins bergamottin, 6’,7’-dihydroxybergamottin and 
bergapten and the glycosidic flavonoids naringin and hesperidin, at 
concentrations found in GFJ or higher did not inhibit the hydrolysis of PNPA by 
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purified porcine esterase and human liver microsomes.  However, the flavonoid 
aglycones morin, galangin, kaempferol, quercetin, and naringenin showed 
appreciable inhibition of PNPA hydrolysis with IC 50 values of 1.8, 2.8, 5.1, 5.9, 
and 110 µM in purified porcine esterase, and 80, 81, 62, 43, and 30 µM in human 
liver microsomes, respectively.  In Caco-2 cells, demonstrated to contain minimal 
CYP3A activity, the permeability coefficient of prodrug lovastatin and enalapril 
was increased in the presence of the active flavonoids kaempferol and 
naringenin, consistent with inhibition of esterase activity.  In rats, oral 
coadministration of kaempferol and naringenin with these prodrugs led to 
significant increases in plasma exposure to the active acids.  Additionally, in 
portal vein cannulated rats coadministration of lovastatin with kaempferol (10 
mg/kg) led to 154% and 113% increase in the portal plasma exposure to the 
prodrug and active acid, compared to coadministration with water.  The 
contribution of CYP3A inhibition was demonstrated to be minimal.  Overall, a 
series of flavonoids present in GFJ are identified as carboxylesterase inhibitors, 
of which kaempferol, and naringenin are shown to mediate pharmacokinetic drug 
interaction with prodrugs lovastatin and enalapril due to their capability of 
esterase inhibition.  We also used two human esterase selective substrates, 
CPT11 and enalapril to investigate the interaction mechanism between GFJ 
flavonoids and esterase. Three GFJ flavonoids kaempferol, quercetin, and 
naringenin showed competitive inhibition on hydrolysis of CPT11 (to SN38) and 
noncompetitive inhibition of hydrolysis of enalapril (to enalaprilat).   
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 7. TABLES                                   
 
 
 
                                    Table1. Percentage remaining of lovastatin in pulp-free GFJ supernatant after the centrifugation of 
                                 lovastatin (20 µM) solutions containing various concentrations of GFJ   
 
GFJ % 
% lovastatin in pulp free GFJ 
supernatant 
0 100 
6.25 92.6 
12.5 87.8 
25 74.1 
50 68.2 
100 64.2 
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              Table2. Effect of the esterase inhibitor BNPP (25 mg/kg PO) on the PK parameters of lovastatin acid  
               and enalaprilat following oral administration of lovastatin and enalapril, respectively, (10 mg/kg) to rats   
 
 
 
 
 
 
 
 
              Data are mean values ± stdev (n=3)  
 
 
 
 
 Enalaprilat Lovastatin acid 
Co-administration AUC0-24hr Tmax Cmax AUC0-24hr Tmax Cmax 
 (nM.hr) (hr) (nM) (nM.hr) (hr) (nM) 
Water 5743 ± 303 1.0 ± 0.0 2543 ± 255 45.3± 6.20 1.3 ± 0.6 10.2 ± 1.25 
BNPP 9006 ±1292 1.0 ± 0.0 3963 ± 1410 109± 12.5 1.0 ± 0.0 34.2 ± 11.6 
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              Table 3. Effect of GFJ (10 mL/kg) on PK parameters of lovastatin acid and enalaprilat following oral administration  
             of lovastatin ( 10 mg/kg) and enalapril (10 mg/kg) to rats  
 
 
 
       Data are mean values ± stdev (n=3)  
 
 
 
 
 Enalaprilat Lovastatin acid 
Co-administration AUC0-24hr Tmax Cmax AUC0-24hr Tmax Cmax 
  (nM.hr) (hr) (nM) (nM.hr) (hr) (nM) 
H20 (pH 3.5) 5743 ± 303 1.0 ± 0.0 2543 ± 255 57.5 ± 24.1 3.3 ± 1.2 14.8 ± 3.3 
GFJ, 1:3 diluted 9465 ±1886 1.0 ± 0.0 4063 ± 635 218 ±140 2.3 ± 1.5 61.0 ± 41.4 
GFJ, 1:2 diluted 9743 ±1560 1.0 ± 0.0 3790 ± 719 148 ± 56.3 4.0 ± 0.0 34.8 ± 12.6 
GFJ, Concentrate 6643 ±1949 4.0 ± 0.0 1443 ± 468 155 ± 38.0 4.0 ± 2.0 38.0 ± 16.1 
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                Table 4. Portal plasma PK parameters of lovastatin acid and lovastatin + lovastatin acid following oral    
                coadministration of lovastatin (10 mg/kg) with water (pH 3.5) or GFJ to portal vein-cannulated rats, pretreated 
                at -15 and -2 hr with water (pH 3.5) or GFJ  
 
 
     Data are mean values ± stdev (n=3)  
 
 
 
 
 
   Lovastatin acid Lovastatin acid + Lovastatin 
Group Pretreatment Co-admi. AUC0-8hr Tmax Cmax AUC0-8hr Tmax Cmax 
  -2 and -15 h   (nM.hr) (hr) (nM) (nM.hr) (hr) (nM) 
A H2O  (pH 3.5) H2O 1949 ± 414 2.4± 1.9 611 ± 122 2678 ± 515 2.4± 1.9 779 ± 140 
B GFJ H2O (pH 3.5) 2897 ± 552 2.5 ± 1.0 792 ± 115 3265 ± 592 2.5 ± 1.0 944 ± 196 
C GFJ GFJ 4209 ± 883 2.8 ± 2.0 1139 ± 187 4880 ± 884 2.8 ± 2.0 1306 ± 149 
 58 
                  Table 5. Portal plasma PK parameters of 6’ß-hydroxylovastatin and its hydroxy acid (6’ß-hydroxylovastatin acid)  
                 following oral administration of lovastatin (10 mg/kg) with water (pH 3.5) or GFJ to portal vein-cannulated rats, 
                 pretreated at -15 and -2 hr with water(pH 3.5) or GFJ  
 
                   
 
       Data are mean values ± stdev (n=3)  
 
 
 
 
   6’ß-Hydroxylovastatin  6’ß-Hydroxylovastatin acid  
Group Pretreatment 
Co-
administration 
AUC0-8hr 
Tmax 
 
Cmax AUC0-8hr 
Tmax 
 
Cmax 
   -2 and -15 h   (nM.hr) (hr) (nM) (nM.hr) (hr) (nM) 
A H2O, pH 3.5 H2O, pH 3.5 1555 ± 290 4.1± 2.6 448 ± 118 740 ± 125 3.1± 2.4 219 ± 65.6 
B GFJ H2O, pH 3.5 186 ± 148 1.8 ± 1.7 94.1 ± 34.2 83.1 ± 22.1 2.4 ± 1.9 51.3 ± 21.2 
C GFJ GFJ 181 ± 62.3 2.3 ± 1.5 114 ± 63.2 77.0 ± 4.9 2.3 ± 1.5 41.9 ± 13.4 
 59 
                 Table 6. Effect of oral pretreatment with GFJ on PK parameters of lovastatin and lovastatin acid following 
                IV administration of lovastatin (2 mg/kg) to rats  
 
 
 
 Data are mean values ± stdev (n=3)  
 
 
 
 
               
 
 
Pretreatment  Lovastatin acid Lovastatin 
(PO) AUC0-2hr CLp Vdss t1/2 AUC0-2hr CLp Vdss t1/2 
-0.5 hr (nM.hr) (L/hr/kg) L/kg (hr) (nM.hr) (L/hr/kg) L/kg (hr) 
Water, pH 3.5 840 ± 154 5.52 ± 1.02 3.61 ± 1.03 0.43 ± 0.06 131 ± 13.0 37.7 ± 3.95 12.5 ± 2.98 0.26 ± 0.01 
GFJ, 1:3 diluted 722 ± 103 6.38 ± 0.97 4.04 ± 0.40 0.43 ± 0.01 108 ± 11.3 45.9 ± 4.64 15.4 ± 2.37 0.30 ± 0.02 
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                   Table 7. Effect of oral pretreatment with GFJ on PK parameters of enalapril and enalaprilat following 
                   IV administration of enalapril (2 mg/kg) to rats  
 
 
 
        Data are mean values ± stdev (n=3)  
 
 
 
 
 
 
Pretreatment   Enalaprilat Enalapril 
(PO) AUC0-24hr CLp Vdss t1/2 AUC0-1hr CLp Vdss t1/2 
-0.5 hr (nM.hr) (L/hr/kg) L/kg (hr) (nM.hr) (L/hr/kg) L/kg (hr) 
Water, pH 3.5 2730 ± 486 2.00 ± 0.31 3.15 ± 1.14 9.7 ± 1.1 152 ± 29.0 38.8 ± 8.18 3.95 ± 0.76 0.10 ± 0 
GFJ, 1:3 diluted 2680 ± 428 2.00 ± 0.32 3.06 ± 0.70 8.4 ± 1.9 144 ± 23.3 40.7 ± 7.23 4.14 ± 0.53 0.10 ± 0 
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                           Table 8. Inhibitory effect of GFJ chemical components toward PNPA hydrolysis in 
                            purified porcine esterases 
 
 
 
 
 
 
 
 
 
 
 
 
                            
 
Inhibitors  Inhibition of PNPA Hydrolysis (%) IC50 (µM) 
Conc. 5 (µM) 50  (µM) 1000 (µM)   
Kaempferol 50 80 na 5.1 
Quercetin 50 82 na 5.9 
Morin 60 90 na 1.8 
Galangin 58 85 na 2.8 
Naringenin <5 27 na 110 
Hesperidin <5 <5 na  na 
Naringin <5 <5 25  na 
Bergamottin <5 23 na  na 
6’,7’-DHB <5 <5 na  na 
Bergapten <5 <5 na  na 
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                            Table 9. Inhibitory effect of GFJ chemical components toward PNPA hydrolysis  
                             in human liver microsomes 
 
 
 
Inhibitors Inhibition of PNPA Hydrolysis (%) IC50 (µM) 
Conc. 5 (µM) 50  (µM) 1000 (µM)  
Kaempferol <5 45 na 62 
Quercetin <5 50 na 43 
Morin <5 40 na 80 
Galangin <5 40 na 81 
Naringenin <5 65 na 30 
Hesperidin <5 <5 na na 
Naringin <5 <5 <5 na 
Bergamottin <5 20 na na 
6’,7’-DHB <5 10 na na 
Bergapten <5 <5 na na 
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                Table10.  Pharmacokinetic parameters of enalaprilat following oral administration of 
                           enalapril (10 mg/kg) to rats and the effect of co-administrated naringenin (2 and 10 mg/kg)  
                           and kaempferol (2 and 10 mg/kg) 
 
 
 
 
 
 
 
 
 
 
 
 
                            Data are mean values ± stdev (n=3)  
 
 
 
 
 Enalaprilat 
Co-admin AUC0-8 hr Tmax Cmax 
 (nM.hr) (hr) (nM) 
Water 5494 ± 2309 0.66 ± 0.28 2163 ± 932 
Naringenin, 2 mg/kg 6473 ± 3162 0.83 ± 0.29 2213 ± 882 
Naringenin, 10 mg/kg 7597 ± 2190 1.0 ± 0.0 2620 ± 436 
Kaempferol, 2 mg/kg 8814 ± 3279 0.5± 0.0 3033 ± 1161 
Kaempferol, 10 mg/kg 11498 ± 3386 0.8 ± 0.2 4830 ± 1939 
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                Table11. Pharmacokinetic parameters of lovastatin acid following oral administration of 
                          lovastatin (10 mg/kg) to rats and the e ffect of co-administrated naringenin (2 and 10 mg/kg)  
                          and kaempferol (2 and 10 mg/kg) 
 
 
 
 
 
 
 
 
 
                           Data are mean values ± stdev (n=3)  
 
 
 
 
 
 
 
 Lovastatin Acid 
Co-admin AUC0-8 hr Tmax Cmax 
 (nM.hr) (hr) (nM) 
Water 32.5 ± 1.1 0.4 ± 0.2 28.5 ± 12.7 
Naringenin , 2 mg/kg 84.1 ± 11.7 1.7 ± 0.6 38.0 ± 6.9 
Naringenin ,10 mg/kg 126  ± 31.2 1.3 ± 0.6 48.9 ± 8.2 
Kaempferol, 2 mg/kg 88.1 ± 16.5 1.6 ± 0.5 41.6 ± 5.2 
Kaempferol,10 mg/kg 112 ± 11.1 0.4 ± 0.14 72.0 ± 42.9 
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                    Table12. Pharmacokinetic parameters of lovastatin, lovastatin acid, and 6’ß-hydroxylovastatin 
                     in portal vein following oral administration of lovastatin (10 mg/kg) with water and kaempferol,10 mg/kg  
 
 
 
 
 
 
 
 
 
                             
 
 
                  Data are mean values ± stdev (n=3)  
 
 
                 
 
 
Co-administration Water Kaempferol, 10 mg/kg 
  AUC0-8 hr Tmax Cmax AUC0-8 hr Tmax Cmax 
  (nM.hr) (hr) (nM) (nM) (hr) (nM) 
Lovastatin 1440 ± 678 2.3 ± 0.7 358 ± 67 3662 ± 990* 2.4 ± 2.0 985 ± 410 
Lovastatin Acid 
 
3960 ± 482 2.1 ±2.5 1042 ± 191 8420 ± 2698* 2.5 ±1.7 2425 ± 946 
6'ß- 
Hydroxylovastatin 93 ± 49 1.6 ± 0.9 60 ± 39 286 ± 143* 3.1 ± 2.0 105 ± 51 
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      Table13.  Parameters of Michaelis-Menten kinetics of CPT11 by purified porcine esterases, and the effect of  
       naringenin, kaempferol, and quercetin  
 
Nargingenin (µM) 
CPT11 
0 15.6 31.2 62.5 125 250 
Vmax 
(pmol/unit/min) 0.56 ± 0.024 na 0.56 ± 0.024 0.57 ± 0.024 0.58 ± 0.018 0.70 ± 0.051 
Km (µM) 4.8± 0.64 na 8.8 ± 0.83 12 ± 1.2 19 ± 1.2 37 ± 4.3 
 Kaempferol (µM) 
 
0 0.13 0.25 0.5 1.0 2.0 
Vmax 
(pmol/unit/min) 
0.60 ± 0.022 0.55 ± 0.038 0.56 ± 0.044 0.52 ± 0.036 0.55 ± 0.025 1.3 ± 0.90 
Km (µM) 5.2 ± 0.58 7.2 ± 1.3 11 ± 2.0 15 ± 2.3 30 ± 2.3 146 ± 124 
 Quercetin (µM) 
 
0 0.13 0.25 0.5 1.0 2.0 
Vmax 
(pmol/unit/min) 
0.59 ± 0.012 0.65 ± 0.024 0.61 ± 0.023 0.56 ± 0.047 0.67 ± 0.066 0.80 ± 0.10 
Km (µM) 4.7 ± 0.29 7.8 ± 0.78 7.5 ± 0.76 7.5 ± 1.6 14 ± 3.0 25 ± 5.7 
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     Table14.  Parameters of Michaelis-Menten kinetics of enalapril hydrolysis by purified porcine esterases, and the  
                      effect of naringenin, kaempferol, and quercetin  
 
 
Nargingenin (µM) 
Enalapril 
0 15.6 31.2 62.5 125 250 
Vmax 
(pmol/unit/min) 38.7 ± 5.07 38.2 ± 8.58 34.1 ± 2.11 40.3 ± 9.74 32.8 ± 4.43 22.6 ± 3.10 
Km (µM) 266 ± 56.9 313 ± 109 212 ± 23.0 361 ± 130 284 ± 61.5 119 ± 34.3 
 Kaempferol (µM) 
 
0 0.13 0.25 0.5 1.0 2.0 
Vmax 
(pmol/unit/min) 38.7 ± 5.07 33.9 ± 5.02 23.5 ± 2.13 25.2 ± 3.44 22.0 ± 2.14 19.6 ± 3.30 
Km (µM) 266 ± 56.9 277 ± 66.2 201 ± 32.5 319 ± 67.3 447 ± 61.6 558 ± 126 
 Quercetin (µM) 
 
0 0.13 0.25 0.5 1.0 2.0 
Vmax 
(pmol/unit/min) 47.1 ± 9.20 44.6 ± 9.71 50.1 ± 17.0 44.6 ± 7.59 25.3 ± 5.18 23.8 ± 4.05 
Km (µM) 291 ± 90.3 300 ± 103 435 ± 210 400 ± 99.0 290 ± 94.1 317 ± 83.6 
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     Table15.  Inhibition constants of kaempferol, quercetin, and naringenin on CPT11 and enalapril  
                    hydrolysis by purified porcine esterases 
 
  
  
 Inhibition Constants, K i (µM) 
 
CPT11  
Hydrolysis 
 Enalapril 
Hydrolysis 
Kaempferol 
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OOH
HO O
OH
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Figure 1.  PNPA hydrolysis by purified porcine esterases
6. FIGURES
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Figure 2.  Inhibition of purified porcine esterase activity by GFJ
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Figure 3.  Inhibition of hydrolysis of (A)lovastatin (5 µM) and (B) 
enalapril (5 µM) in human intestinal and liver S9
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Figure 4. Inhibition of hydrolysis of lovastatin (5 µM) in (A) rat intestinal 
and liver S9 (B) intestinal lumen by GFJ
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Figure 6. CYP3A activity of Caco-2 homogenates
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Figure 7. Hydrolysis of lovastatinby Caco-2 homogenates
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Figure 8.  Effect of GFJ on (A) lovastatin AàB permeability across
Caco-2 membrane (B) ratio of lovastatin acid and lovastatin
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(A)
(B)
76
010
20
30
40
50
0 6.25 12.5 25 50
% GFJ
T
ra
ns
po
rt 
of
 E
na
la
pr
il 
ac
ro
ss
 C
ac
o-
2 
(p
m
ol
/ h
-1
) 
0
2
4
6
8
10
0 6.25 12.5 25 50
% GFJ
In
tr
ac
el
lu
la
r C
on
ce
nt
ra
tio
n 
R
at
io
 
of
 E
na
la
pr
ila
t a
nd
 E
na
la
pr
il 
in
 
C
ac
o-
2 
C
el
ls
  a
t 1
.0
 h
r
Figure 9.  Effect of GFJ on (A) enalapril AàB permeability across Caco-2
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TIC of +Q1: from Sample 11 (Sample002(-) NADPH full) of 20060726_Hmic_HySET1.wiff (Turbo... Max. 1.6e9 cps.
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Figure11.   Full scan mass chromatogram (150-600 m/z) of incubation mixtures 
of lovastatin in human liver microsomes w/o NADPH
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TIC of +Q1: from Sample 10 (Sample001(NADPH) full) of 20060726_Hmic_HySET1.wiff (Turbo ... Max. 8.7e8 cps.
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Figure12.   Full scan mass chromatogram (150-600 m/z) of incubation mixtures of 
lovastatin in human liver microsomes w/ NADPH
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XIC of  +Q1 MI (4 ions) :  405.5 amu f rom Sample 4 (Sample001(NADPH),  s im) of  20060726_Hmic. . . Max.  1 .7e6 cps.
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Figure13.  SIM scan (m/z 405.5) of incubation mixtures of lovastatin in 
human liver microsomes w/ NADPH
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TIC of +MS2 (423.40) CE (30): from Sample 14 (Sample001(NADPH) full) of 20060726_Hmic_H... Max. 3.1e6 cps.
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Figure14.  SIM scan (m/z 423.4) of incubation mixtures of lovastatin in
human liver microsomes w/ NADPH
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XIC of +Q1: 321.0 to 322.0 amu from Sample 10 (Sample001(NADPH) ful l )  of  20060726_Hmic_.. . Max.  3.5e7 cps.
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Figure15.  Single ion (m/z 321.5) extracted from full scan (150-600 m/z)
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XIC of +Q1 MI (4 ions):  421.3 amu from Sample 4 (Sample001(NADPH), s im) of 20060726_Hmic.. . Max. 4.2e6 cps.
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Figure16. SIM scan (m/z 421.4) of incubation mixtures of lovastatin
in human liver microsomes w/ NADPH
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Figure 17.   SIM scan (m/z 439.4) of incubation mixtures of lovastatin
in human liver microsomes w/ NADPH
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 +MS2 (405.50) CE (30): 8.158 min from Sample 12 (Sample002(-) NADPH full) of 20060726_Hmic_HyS... Max. 6.1e6 cps.
160 180 200 220 240 260 280 300 320 340 360 380 400 420 440
m/z, amu
5.0e5
1.0e6
1.5e6
2.0e6
2.5e6
3.0e6
3.5e6
4.0e6
4.5e6
5.0e6
5.5e6
6.0e6
199.4
225.1
243.4
173.1
249.1201.3
223.3
239.3159.4 285.1
169.4
267.0157.4 197.3 211.3191.1
215.6
185.4 229.1207 .3 303.3161.4 221.4187.3 241.4 257.1219.9 321.5261.3 283.5
Figure 18.  MS/MS of lovastatin (m/z 405.3)
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 +MS2 (423.40) CE (30): 7.354 to 7.521 min from Sample 14 (Sample001(NADPH) full) of 20060726_Hm... Max. 2.5e4 cps.
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Figure19.  MS/MS of lovastatin acid (m/z 423.3)
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Figure 20.  MS/MS of hydroxylovastatin m/z 421.3, retention time (tR) 5.02 min
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Figure 21.  MS/MS of hydroxylovastatin m/z 421.3, tR 6.19 min.
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 +MS2 (439.40)  CE (30) :  5 .528 to  5 .829 min f rom Sample 15 (Sample001(NADPH) fu l l )  o f  2006. . . Max.  7265.6 cps.
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Figure 22.  MS/MS of hydroxylovastatinacid m/z 439.3, tR 4.36 min.
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Figure 23. MS/MS of hydroxylovastatin acid m/z 439.3, tR 5.67 min.
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Figure 24.  Effect of the esterase inhibitor BNPP (25 mg/kg PO) on 
the plasma concentration-time profiles of (A) enalaprilat and (B) lovastatinacid
following oral administration of enalapril and lovatatinat 10 mg/kg, respectively
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Figure 25.  Plasma concentration-time profiles of (A) enalaprilat and 
(B)lovastatinacid following oral administration of enalapril and lovastatin
at 10 mg/kg with water or GFJ (1:3. 1:2, Concentrate), respectively
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Figure 26.   Portal plasma concentration-time profiles of (A) lovastatinacid 
(B) lovastatin acid + lovastatin following oral administration of lovastatin
(10 mg/kg) with water (pH 3.5) or GFJ to portal vein-cannulated rats, 
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lovastatin as standard
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Figure 27.  Portal plasma concentration-time profiles of (A) 6’ß -hydroxy
lovastatin (B) 6’ß -hydroxylovastatin acid following oral administration of 
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Figure 28. PNPA hydrolysis by human liver microsomes
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Figure 29.  Inhibition potential of purified porcine esterases by (A) naringin
and (B) hesperidin
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Figure.30  Inhibition potential of purified porcine esterases by (A) bergamottin
(B) 6’,7’-dihydroxybergamottin, and (C) bergapten
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Figure 31.  Inhibition potential of purified porcine esterases by (A) kaempferol
(B) quercetin, and (C) naringenin
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Figure 32.  Inhibition potential of purified porcine esterases by (A) morin
(B) galangin, and (C) BNPP 
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Figure 33.  Inhibition potential of esterases of human liver microsomes by 
(A) naringin and (B) hesperidin
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Figure 34. Inhibition potential of esterases of human liver microsomes by
(A) bergamottin,(B) 6’,7’-dihydroxybergamottin, and (C) bergapten
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Figure 35.  Inhibition potential of esterases of human liver microsomes 
by (A) kaempferol, (B) quercetin, and (C) naringenin
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Figure 36.   Inhibition of esterases of human liver microsomes by
(A) morin, (B) galangin, and (C) BNPP
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Figure 37.  Effect of grapefruit juice constituents on (A) lovastatin AàB 
permeability across Caco-2 membrane (B) ratio of lovastatinacid 
and lovastatin in Caco-2 cells at 1 hr
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Figure 38.  Effect of grapefruit juice constituents on (A) enalapril AàB 
permeability across Caco-2 membrane (B) ratio of enalaprilat
and enalapril in Caco-2 cells at 1 hr
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Figure 39.  Plasma concentration-time profiles of enalaprilat following 
oral administration of enalapril at 10 mg/kg with (A) water or kaempferol
(2 and 10 mg/kg) (B) water or naringenin (2 and 10 mg/kg)
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Figure 40.  Plasma concentration-time profiles of lovastatin acid following 
oral administration of lovastatinat 10 mg/kg with (A) water or naringenin
(2 and 10 mg/kg) (B) water or kaempferol (2 and 10 mg/kg)
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Figure 41.  Portal plasma concentration-time profiles of (A) lovastatin acid
(B) lovastatin, and (C) 6’ß -hydroxylovastatin following oral administration
of lovastatin (10 mg/kg) with water or kaempferol (10 mg/kg) to rats
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Figure 42.  Chemical hydrolysis of (A) CPT11 (B) enalapril in 0.1 M 
phosphate buffer, pH, 4.6, 7.0, and 8.0
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Figure 43.   Michaelis-Menten kinetics of CPT11hydrolysis in human 
liver microsomes and S9 fractions
111
0.0500.026CL, L/hr/kg
0.050.03Clint, L/hr/kg
4.74.6km, nmol/ml
0.0740.134Vmax nmol/hr/mg
S9Microsomes
0 5 10 15 20
0
50
100
150 Micrsomes
S9
CPT11, mM
S
N
38
 fo
rm
at
io
n,
 p
m
ol
/m
g/
hr
Figure 44.   Michaelis-Menten kinetics of enalapril hydrolysis in human 
liver microsomes and S9 fractions
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Figure 45.  Michaelis-Menten kinetics of CPT11 hydrolysis by purified
porcine esterases, and the effect of kaempferol (A) Direct plot (B) 
Primary Lineweaver-Burk plot 
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Figure 46.  Michaelis-Menten kinetics of CPT11 hydrolysis by purified
porcine esterases, and the effect of quercetin (A) Direct plot and (B)
Primary Lineweaver-Burk plot
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Figure 47. Michaelis-Menten kinetics of CPT11 hydrolysis by purified
porcine esterases, and the effect of naringenin (A) Direct plot and
(B) Primary Lineweaver-Burk plot
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Figure 48.  Michaelis-Menten kinetics of enalapril hydrolysis by purified
porcine esterases, and the effect of kaempferol (A) Direct plot and (B)
Eadie-Hofstee plot
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Figure 49.    Michaelis-Menten kinetics of enalapril hydrolysis by purified
porcine esterases, and the effect of quercetin (A) Direct plot and (B)
Eadie-Hofstee plot
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Figure 50.  Michaelis-Menten kinetics of enalapril hydrolysis by purified
porcine esterases, and the effect of naringenin (A) Direct plot and (B)
Eadie-Hofstee plot
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Figure 51.  Metabolism of lovastatin in human liver microsomes
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Figure 52.  Structures of studied carboxyl esters and corresponding free acids
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Figure 53.  Structures of studied GFJ chemical components
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Figure 54.  Structures of PMSF, BNPP, Gly-Sar, and GF120918 
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